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General introduction, 




Diabetes and cardiovascular disease
Type 2 diabetes is becoming a pandemic [1].  The prevalence of diabetes not only 
increases in western societies but also in developing countries [2]. Central in the 
pathogenesis of  type 2 diabetes is reduced insulin-sensitivity of  glucose-utilizing 
tissues (insulin resistance). Insulin resistance in its turn is strongly associated 
with - mainly visceral- obesity. Both genetic and environmental factors are involved 
in diabetogenesis.
Diabetic subjects have an increased incidence of both macrovascular (coronary 
artery events, stroke, peripheral artery disease) and microvascular (nephropathy, 
retinopathy) disease. Multiple factors contribute to vascular damage, including 
direct toxic effects of high glucose levels to the vasculature, dyslipidemia and 
hypertension. Several large-scale intervention trials targeting these factors 
have shown that the incidence of cardiovascular disease in type 2 diabetic 
subjects can be significantly reduced [3,4,5].
South Asians, central obesity and type 2 diabetes
In western societies, subjects of South Asian descent have an increased 
prevalence of insulin resistance and  type 2 diabetes [6,7]. Besides exogenous 
factors like excessive energy ingestion [8] and diminished physical activity [9], 
genetic factors clearly play a role. Compared to Caucasians, body composition 
is different in South Asians. South Asians have a preferential truncal (deep 
adipose tissue) fat distribution [10], and even at the same body mass index the 
amount of  -mainly visceral- fat is increased in South Asians [11]. Central 
obesity is associated with insulin resistance [7]. Compared to the relatively 
inactive superficial subcutaneous fat (primary compartment), deep 
subcutaneous and visceral fat (secondary compartment) is an active regulator 
of body metabolism [12].
Not only fat distribution is different in South Asians, adipose tissue function is 
also different [13]. The relationship between insulin sensitivity and adiposity is 
much stronger in South Asians than in Caucasians [10].  Even when central 
obesity has not (yet) developed, South Asian children have decreased insulin 
sensitivity compared to Caucasian children [14]. In South Asians, insulin 
resistance is already present at birth [15]. 
Several hypotheses try to explain the increased tendency to central obesity and 
the apparent adipose tissue dysfunction in South Asians. Chronic energy 
depletion and climatic influences may have favoured energy storage in the 
quickly mobilizable deep adipose tissue compartment, making fat metabolism 
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in South Asians more sensitive to fluctuations in energy supply (el-Nino 
hypothesis) [16]. Alternatively, differences in mitochondrial gene structure and 
function (favouring energy storage at the cost of heat production)  might 
explain the tendency to central obesity in South Asians  (the “mitochondrial 
efficiency hypothesis“) [17].    
Besides its function as an energy storage pool, adipose tissue -especially the deep 
compartment- plays an important role in immune system maintenance [18-20]. 
A high burden of  - mainly gastrointestinal - infectious diseases may have resulted 
in the tendency to prioritize deep visceral adipose tissue depots to meet the 
immediate demands of the immune system in the defeat of gastrointestinal 
pathogens, as postulated by the “variable disease selection hypothesis” [21]. 
South Asians and cardiovascular disease
Besides an increased prevalence of central obesity and type 2 diabetes, South 
Asians also have an increased incidence of cardiovascular disease, especially 
coronary artery disease and stroke. This is especially true for South Asian 
immigrants in western societies  [22-23], but also for South Asians living in the 
Indian subcontinent [24]. Although classical risk factors like smoking, 
hypertension and hypercholesterolemia do contribute to cardiovascular 
morbidity in South Asians [25], they are not excessive or more prevalent in 
comparison with Caucasians and hence do not account for the higher rate of 
cardiovascular disease. Moreover, the higher prevalence of type 2 diabetes in 
South Asians also fails to fully explain the excessive cardiovascular morbidity 
[26]. Several other potential cardiovascular risk factors have been studied, 
including hemostatic factors, inflammatory parameters and metabolic factors. 
South Asians have higher levels of plasminogen activator inhibitor 1 (PAI-1) , 
fibrinogen and homocystein, indicating an increased thrombotic tendency 
[27-29]. South Asians also have higher levels of high-sensitivity C-reactive 
protein [30], lipoprotein(a) [31] and decraesed levels of adiponectin [32]. However, 
all the above-mentioned factors were examined in cross-sectional studies, and 
prospective studies addressing their use in predicting cardiovascular disease 
are lacking.
Not only macrovascular complications are increased, South Asians with type 2 
diabetes also have an increased rate of microvascular (renal and retinal) 
complications [33-35]. Type 2 diabetic South Asians have a 40-fold increased 
risk for end-stage diabetic nephropathy [36]. In non-diabetic South Asians, 
central obesity is an independent risk factor for albuminuria [37].   
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Central obesity, cardiovascular disease and the complement system
As recognized by the “variable disease selection hypothesis” (see above), adipose 
tissue function and immunity are closely related [18-20]. South Asian ancestors 
faced a high pressure of - mainly gastrointestinal- infectious diseases. This 
might have set the immune system at a higher level of activity, with adipose 
tissue as a potential mediator. Although protective when faced with infections, 
enhanced immune activity might turn out to be harmful with respect to 
cardiovascular disease in the context of excessive energy supply and diminished 
infectious pressure. Central obesity itself is associated with low grade 
inflammation, reflected by increased levels of C-reactive protein [27]. In South 
Asians however, complement factor C3 is even more closely related to the 
metabolic syndrome (a clustering of cardiovascular risk factors with central 
obesity as a central feature) than CRP [38], and gene expression and production 
of several complement factors has been described in -mainly visceral- adipose 
tissue [39,40].
The complement system is a key player in the innate immune response, and its 
involvement in cardiovascular disease is increasingly being recognized [41,42]. 
The complement system refers to a cascade of proteins which are involved in 
opsonisation of harmful particles such as bacteria and facilitate the 
inflammatory response by attraction of inflammatory cells and enhancing 
vascular permeability. 
The complement system can be activated via three pathways: the classical 
pathway, the alternative pathway and the lectin pathway. These three pathways 
converge into a C3 convertase, and from this point the cascade follows a final 
common pathway leading to the formation of C5b-9, also known as the 
Membrane Attack Complex (MAC). The Membrane Attack Complex  induces cell 
damage by creating pores in the cellular membrane leading to osmotic cell 
swelling and subsequent cell death, but sublytic effects have also been described 
[43]
The classical pathway is activated by immune complexes and involves factor 
1,2 and 4. The alternative pathway is dependent on the stabilisation of 
spontaneously hydrolysed C3. In addition, recent evidence suggests that 
properdin might act as the primary recognition molecule in the alternative 
pathway. The lectin pathway, which  also involves factor 2 and 4, is activated 
when Mannan Binding Lectin (MBL) binds to carbohydrate residues present on 
various pathogenic surfaces. Activation products of the complement system 
have been detected in atherosclerotic plaques and in kidneys and urine of 
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diabetic subjects [44-46], and MBL has recently evolved as a cardiovascular and 
renal risk marker [47-49]. 
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Figure 1    the complement system
Complement activation occurs via the classical pathway (initiated by the binding of immuno-
globulins to antigens) , the lectin pathway (initiated by the binding of Mannose Binding Lectin 
(MBL) or ficolins to sugar residues), or the alternative pathway. The latter pathway is spontaneously 
activated by slow hydrolysis of C3.  The alternative pathway also serves as an amplification loop 
for the classical and lectin pathway. Recent evidence suggests that binding of properdin to its 
ligand initiates the alternative pathway. All three pathways converge into a C3 convertase, and 
from this point the cascade follows a final common pathway leading to the formation of C5b-9, 
also known as Terminal Complement Complex (TCC) or Membrane Attack Complex (MAC), which 
induces damage to the cell membrane leading to cell death. Cleavage products of C3 and C5 
facilitate the inflammatory response. (prof. T.E.Mollnes, reprinted with permission)
15
Scope of this thesis
The high rate of cardiovascular complications in type 2 diabetic South Asians, 
the above-mentioned relationship between central obesity and immune 
function and the participation of the complement system in vascular damage 
led us to explore the association of the complement system and vascular 
complications in type 2 diabetic South Asians. We hypothesized that the 
activity of the complement system is enhanced in South Asians compared to 
Caucasians and that this contributes to the increased susceptibility to vascular 
and renal complications in type 2 diabetic South Asians.
Study population
The studies were accomplished in a population of immigrants of South Asian 
descent living in The Hague and surroundings. The ancestors of these South 
Asians originally came from the Indian Subcontinent, in a circumscriptive 
area of North India called Uttar Pradesh, Uttarakhand and West-Bihar [50]. In 
the late 19th century, some 30.000 inhabitants of this region migrated to 
Suriname to work on the plantations. The independence of Suriname in 1975 
and the unstable political climate afterwards led many South Asians to migrate 
to the Netherlands where they took residence mainly in The Hague, Rotterdam 
and Amsterdam. In the South Asian population in the Hague, type 2 diabetes 
was shown to be very common, with a prevalence of 40% in those over the age 
of 60  [51].
The studies described in this thesis are an extension of the  previously conducted 
HINDINEF study [52]. The study population comprised 169 first-degree relatives 
of South Asian subjects with end-stage renal disease due to diabetic nephropathy, 
161 first-degree relatives of type 2 diabetic South Asians without diabetic 
nephropathy, 43 subjects already known with diabetes but without nephropathy, 
and 92 “otherwise interested” South Asians (second-degree relatives and 
spouses). The total population consisted of 465 South Asians. As stated above 
[51], in this population having a first-degree relative with type 2 diabetes is 
common rather than exceptional. Out of these 465 subjects, 168 subjects had 
type 2 diabetes at baseline according to the ADA 2003 criteria. Between 2007 
and 2009, follow-up data of these 168 type 2 diabetic subjects were collected. 
Out of these 168 type 2 diabetic subjects, 54 subjects also underwent vascular 
function testing. The results of this follow-up study are described in this 
thesis 
1general introduction, study objectives and thesis-outline
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chapter 1
Figure 2    study population
(
Original HINDINEF study population (n=465)
 - 169 first-degree relatives of type 2 diabetic South Asians with end-stage renal disease
  due to diabetes
 -  43 subjects known with diabetes but without albuminuria
 -  161 first-degree relatives of type 2 diabetic South Asians without albuminuria
 -  92 “otherwise interested”  South Asians (second-degree relatives, spouses)
168 South Asians with type 2 diabetes 
at baseline  according to the ADA 2003 
criteria
Cross-sectional studies in Chapter 2 and 3
134 subjects with available follow-up data
Prospective studies in chapter 2,3 and 6
54 South Asians with type 2 diabetes 
undergoing vascular function testing
Chapter 7
Not related to the South Asian study population:
70 patients with various proteinuric renal disease
Chapter 5
100 randomly selected  South Asians 
without diabetes
Chapter 2 and 3
34 subjects lost to follow-up
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Thesis outline
As the primary focus of this thesis is on the complement system, chapter 2 - 5 
focus on the complement system as a determinant of cardiovascular and renal 
disease. 
Chapter 2 consists of a cross-sectional study comparing levels of complement 
factor 3 and SC5b-9 –the soluble end product of complement activation- in 
South Asians and Caucasians and assessing the relation between C3, SC5b-9, 
Mannose-binding lectin (MBL) and renal damage as reflected by urinary 
albumin/creatinin ratio. In addition, in a prospective observational part the 
predictive value of complement factors for the occurrence of cardiovascular 
events (C3, SC5b-9) and progressive renal failure (C3, SC5b-9, MBL) is studied.  
Chapter 3 is a prospective observational study assessing the relationship 
between Mannose-binding lectin, serum MBL levels and the occurrence of 
coronary artery events. 
In chapter 4 and 5 we study the role of the complement system in the 
pathogenesis of progressive renal failure. The focus is on properdin, a promotor 
of the alternative pathway complement activation.
Chapter 4 describes experimental studies on the role of properdin in 
complement activation on cultured proximal tubular epithelial cells.
Chapter 5 assesses the association between urinary properdin excretion, 
intrarenal complement activation and renal function. This study was done  in 
seventy patients with proteinuria, mainly Caucasians. 
Chapter 6 is a prospective observational study assessing the predictive value of 
waist-to-hip ratio, a measure of central obesity, for cardiovascular events in 
type 2 diabetic South Asians.
Chapter 7 is a cross-sectional study addressing the relationship between plasma 
Connective Tissue Growth Factor (CTGF) – a pro-fibrotic cytokine – and vascular 
damage as assessed by vascular function testing. This study was performed in 
54 type 2 diabetic South Asians. 
1general introduction, study objectives and thesis-outline
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South Asian immigrants in Western societies exhibit a high burden of diabetes 
and subsequent vascular complications. Diabetic vascular complications are 
associated with vascular inflammation. We hypothesize that enhanced 
complement activation is involved.
Research desing and methods 
Levels of complement C3, SC5b-9 -the soluble end-product of complement 
activation, and Mannose- Binding Lectin (the recognition molecule of the lectin 
pathway of complement activation) were measured  in 268 South Asians (168 
type 2 diabetic and 100 non-diabetic subjects) and compared to an age- and sex 
matched control-group of native Caucasians. In a cross-sectional study, the 
association between complement levels, diabetes and  albuminuria was 
assessed. In a longitudinal study, the 168 type 2 diabetic South Asians were 
followed prospectively for a median duration of 7.66 years. The association of 
complement levels with future cardiovascular events and progressive renal 
failure was assessed.
Results
Compared to native Caucasians, South Asians had significantly higher levels of 
both serum C3 and plasma SC5b-9 and higher levels of MBL. A SC5b-9 level 
above the median was associated with albuminuria at baseline (univariate OR 
2.3, 95%CI 1.18-4.55, P = 0.015 ) and with progressive renal failure (univariate 
HR 5.45, 95%CI 1.52-19.5, P = 0.009 ) Neither C3 nor SC5b-9 predicted 
cardiovascular events. Baseline MBL levels were associated with  progressive 
renal failure (multivariate HR 3.59, 95%CI 1.30-9.93, P = 0.014) 
Conclusion
These results suggest that complement activation is involved in the pathogenesis 




South Asian immigrants in Western societies have a high burden of ischemic 
heart disease, stroke and diabetes [1,2]. In addition to macro-vascular disease, 
South Asians also have an increased incidence and a faster rate of progression 
of diabetic nephropathy compared to Caucasians.[3]
Traditional cardiovascular risk factors do not completely explain the increased 
incidence of cardiovascular disease in South Asians [4]. Hence other factors 
must be involved. 
Atherosclerosis, the pathologic substrate of macro-vascular disease, is 
recognized to be an inflammatory process [5-7]. Micro-vascular disease such as 
diabetic nephropathy has also been linked to inflammatory markers [8,9]. As a 
key-player in the inflammatory response, the complement system has been 
implicated in this vascular inflammation [10-12]. Deposition of complement 
components has been demonstrated in atherosclerotic plaques, retinae and 
kidneys of diabetic subjects [13-15] . Complement activation products also have 
been detected in urine of subjects with diabetic nephropathy [16].
The complement system can be activated via the classical, alternative or lectin 
pathway. All three pathways converge into the generation of a C3 convertase, 
which activates the central molecule C3. The final activation product, C5b-9, 
exerts lytic and non-lytic harmful effects to its target cells. The lectin pathway 
is activated when Mannose-Binding Lectin (MBL) binds to its target molecule. 
MBL binds carbohydrate moieties on microorganisms, but endogenous MBL 
ligands, such as glycosylated immunoglobulins or cells exposed to oxidative 
stress, have also been identified [17]. MBL serum levels are primarily determined 
by 3 polymorphisms (B,C and D genotypes, commonly referred to as O-alleles) 
in the MBL gene (mbl2). Subjects with wild type MBL genotype (A/A) have the 
highest serum MBL levels, subjects with 1 variant allele (A/O) have intermediate 
levels and subjects with 2 variant alleles (O/O) have the lowest levels. In addition, 
polymorphisms in the promoter region influence the MBL level [18]. MBL is 
synthesized in the liver. Although intra-individual levels are relatively stable 
over time [19], a two- to threefold increase occurs during acute phase reactions 
[20]. MBL has recently been implicated in the pathogenesis of diabetic vascular 
complications [21].
We hypothesized that in South Asians the complement system contributes to 
the increased susceptibility for vascular and renal disease. We therefore 
examined complement, as judged by the level of the main component C3, the 
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level of the final activation product SC5b-9 and MBL in South Asian subjects 
with and without type 2 diabetes living in the Netherlands, and compared 
these to complement levels in an age- and sex-matched group of native Caucasian 
volunteers without diabetes. In addition, we examined the predictive value of 
serum C3, plasma SC5b-9 and serum MBL level for the occurrence of 
cardiovascular events and progressive renal failure.
Materials & methods
Study design and study population
This study consists of 2 parts: a cross-sectional case-control study and an 
observational follow-up study.
Cross-sectional study
At baseline, 268 South Asians were studied. All subjects were participants in a 
previously conducted study and had been recruited as described earlier [22]. At 
baseline, 168 subjects had type 2 diabetes according to the ADA  2003 criteria. 
In addition, a sample of 100 non-diabetic subjects out of the original study 
population (n=465) was studied. Levels of complement C3, which plays a pivotal 
role in complement activation, and SC5b-9, the soluble end-product of 
complement activation, were measured and compared to levels in a group of 
native Caucasians without diabetes, recruited from healthy personnel from 
the dialysis ward and laboratory (n=60). Complement levels in South Asians 
with diabetes were compared to South Asians without diabetes. In the diabetic 
South Asian subgroup, the association between complement levels and 
albuminuria was assessed.
Follow-up study
After a median duration of 7.66 (IQR 7.48-8.10) years, follow-up data from the 
168 type 2 diabetic subjects were collected. Study-patients were followed up by 
letter and subsequently by phone. When subjects could not be traced by address 
or phone number in our database, general practitioners or participating family 
members were involved. 
Follow-up data consisted of medical history with regard to cardiovascular 
events. Subjects were sent a questionnaire and were invited for a visit to our 
out-patient clinic. During this visit the questionnaire was reviewed by the 
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main investigator (M.A.S.). Subjects not willing to visit the out-patient clinic 
were asked permission to collect medical data from their general practitioner. 
For subjects who had died during the follow-up period, cause of death and 
cardiovascular history was retrieved from the general practitioner. All (self-)
reported events were verified by contacting the hospital in which the event had 
occurred. In addition, renal data (serum creatinine, urinary albumin/creatinin 
ratio) were measured or obtained from the general practitioner. The association 
of baseline complement levels with cardiovascular events and renal 
deterioration was assessed.
The study protocol was approved by the Institutional Medical Ethics Committee. 
All subjects provided informed consent.
Measurement of baseline parameters
The study protocol has previously been published in detail [22]. Briefly, from all 
subjects morning urine and fasting blood samples were taken and immediately 
put in ice. Ethylenediaminetetraacetic acid (EDTA) plasma was obtained after 
centrifugation (10 minutes at 4,000 rpm at 4 degrees Celsius) and the samples 
were stored in aliquots at -80º Celsius within 1 hour after collection. Serum 
was prepared by coagulation at room temperature, and after centrifugation 
the samples were stored at -80º Celsius. All study participants, except known 
diabetic subjects, were subjected to an oral glucose tolerance test (75 gram 
glucose load). Diabetes was diagnosed based on the American Diabetes 
Association 2003 criteria. A brief physical examination (blood pressure, length, 
weight, hip- and waist circumference) was performed. Clinical information 
concerning medical history and medication was obtained from a questionnaire. 
Laboratory measurements including creatinin, fasting lipid profile, HbA1c, 
and urinary albumin/creatinine (ACR) ratio were measured according to 
standard methods. High-sensitivity C-reactive protein (hsCRP) was measured 
with a fully automated Cobas Integra 800, according to the manufacturers 
protocols (Roche, Almere, the Netherlands). 
Quantification of SC5b-9
SC5b-9 levels were assessed by sandwich ELISA. In brief, 96-well ELISA plates 
were coated with the monoclonal antibody aE11 (mouse IgG2a anti-C5b-9 3mg/
ml), described in detail previously [23]. Plasma samples were diluted 1/5 and 
1/20 and incubated in the coated wells. Bound SC5b-9 was detected with a 
biotin labeled monoclonal anti C6 antibody (9C4), followed by detection with 
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streptavidin-poly horse radish peroxidase (Sanquin, Amsterdam, The Netherlands). 
Enzyme activity was detected using 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic 
acid) (Sigma Chemical Co., St. Louis, MO). The optical density was measured at 
415nm using a microplate biokinetics reader (EL312e; Biotek Instruments, 
Winooski, VT). A calibration line was produced using zymosan activated serum 
with a known concentration of SC5b-9 of 1000 U/ml.
Quantification of C3
Serum C3 was quantified using radial immunodiffusion according to Mancini, 
using a polyclonal rabbit anti human C3 antiserum as described earlier [24].
Quantification of  MBL 
At baseline, serum MBL levels were assessed by sandwich ELISA as described 
previously [25]. In brief, 96-well ELISA plates (Greiner, Frickenhausen, Germany) 
were coated with the monoclonal antibody 3E7 (mouse IgG1 anti-MBL at 2.5 µg/
ml), kindly provided by Dr. T. Fujita (Fuhushima, Japan). Serum samples were 
diluted 1/50 and 1/500 and incubated in the coated wells. MBL was detected 
with Dig-conjugated 3E7. Detection of binding of Dig-conjugated antibodies 
was performed using HRP-conjugated sheep anti-Dig Abs (Fab fragments, Roche, 
Mannheim, Germany). Enzyme activity was detected using 2,2'-azino-bis(3-eth-
ylbenzthiazoline-6-sulfonic acid) (Sigma Chemical Co., St. Louis, MO)). The 
optical density was measured at 415nm using a microplate biokinetics reader 
(EL312e; Biotek Instruments, Winooski, VT). A calibration line was produced 
using human serum from a healthy donor with a known concentration of MBL. 
Earlier studies indicated that this assay primarily detects wildtype MBL in 
serum and plasma and that there is a direct association with the MBL genotype 
and with MBL function.
MBL genotyping
DNA was isolated routinely from peripheral blood leucocytes. MBL single 
nucleotide polymorphisms at codons 52, 54 and 57 of the mbl2 gene were typed 
by pyrosequencing. The detailed methodology has been published separately 
[26]. The MBL genotype of only wild-type allele carriers is designated as A/A and 





Albuminuria was defined as a urinary albumin/creatinine ratio > 2.5 mg/mmol 
in men and > 3.5 mg/mmol in women.
Cardiovascular events were pre-defined as the occurrence of either a myocardial 
infarction, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary 
Artery Bypass Grafting (CABG), stroke, Carotid Artery Desobstruction, 
peripheral vascular angioplasty, bypass or amputation, or sudden cardiac 
death. The latter was defined as a witnessed sudden circulatory arrest. The 
primary end-point was the time to the first cardiovascular event. 
Progressive renal failure was arbitrarily pre-defined as a 50% increase in serum 
creatinine or the initiation of renal replacement therapy (dialysis or kidney 
transplantation)
Statistical analysis
Normally distributed variables are expressed as mean ± 1 standard deviation 
and skewed distributed variables as median and interquartile range. Differences 
between two groups were assessed by Student’s t-test or Mann-Whitney-U test 
as appropriate. Correlations were assessed by Pearson’s or Spearman’s 
correlation as appropriate. Associations between complement levels and 
albuminuria were assessed with logistic regression . Associations between 
complement levels, cardiovascular events and progressive renal failure were 
assessed with Cox proportional hazards regression. All test were two-sided and 




Two hundred sixty-eight South Asians (168 diabetic and 100 non-diabetic 
subjects) were studied. Of the 168 diabetic subjects, 121 were already known 
with diabetes at the time of the study, and 47 subjects were newly diagnosed 
with diabetes based on oral glucose tolerance testing. In the diabetic group, 53 
subjects had albuminuria, and in the non-diabetes group 2 subjects had 
albuminuria. Characteristics of the South Asian study population are shown in 
Table 1.
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Age and sex were not significantly different between the whole South Asian 
and Caucasian group (mean age 48.8  ± 10.2 versus 46  ± 8 , P = 0.10 and % male 
sex 46 versus 45, P = 0.9, respectively) . 
Complement levels in South Asians compared to native Caucasians
Serum C3 in the whole South Asian group was significantly higher compared to 
native Caucasians (867 ± 115 µg/ml versus 580 ± 128µg/ml, P<0.001) (Figure 1). 
When considering only non-diabetic South Asians, they still had higher C3 levels 
than native Caucasians (854 ± 139 µg/ml versus 580 ± 128 µg/ml, P<0.001).
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Table 1    baseline characteristics of 268 South Asians





Age (yrs) 50.5 ± 11.3 46 ± 7.3 < 0.001
% male sex 46 47 0.97
Diabetes duration (yrs) 7.0 (0.0-13.0) -
HbA1c (%) 7.7 ± 1.9 -
Current or former smoker (%) 44 31 0.037
Body Mass Index 28.1 ± 4.5 26 ± 4.0 < 0.001
Waist circumference (cm) 97.2 ± 14.5 91.0 ± 10.3 < 0.001
Waist-to-hip ratio 0.98 ± 0.08 0.92 ± 0.08 < 0.001
Systolic blood pressure (mm Hg) 139 ± 25 128 ± 17 < 0.001
Diastolic blood pressure (mm Hg) 84 ± 11 81 ± 10 0.016
Total cholesterol (mmol/L) 5.1 ± 0.97 5.3 ± 0.97 0.082
Fasting triglycerides (mmol/L) 1.5 (1.2-2.2) 1.2 (0.84-1.88) < 0.001
Ratio total: HDL cholesterol 4.33 ± 1.22 4.17 ± 1.24 0.318
Cockroft-Gault creatinin 
clearance (ml/min)
93 ± 31 86 ± 17 0.012
Urinary albumin/creatinine ratio 
(mg/mmol)
1.0 (0.39-4.75) 0.32 (0.20-0.63) < 0.001
hs CRP (mg/L) 3.5 (1.8-8.3) Not available
Serum C3 (µg/ml) 875 ± 97 854 ± 139 0.184
Plasma SC5b-9 (U/ml) 0.35 ± 0.15 0.36 ± 0.13 0.708
Serum MBL (µg/L) 476 (143-1563) 1009 (239-1847) 0.043
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South Asians also had signifi cantly higher plasma levels of SC5b-9, the soluble 
end-product of complement activation (mean 0.358 ± 0.14 U/ml versus 0.149 ± 
0.07 U/ml, P<0.001) (Figure 1b). This was also the case when considering only 
non-diabetic South Asians (0.362 ± 0.13 U/ml versus 0.149 ± 0.07 U/ml, P< 0.001). 
MBL levels in the whole South Asian group were higher than in the Caucasian 
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Figure 1   
Serum concentration of C3 (upper panel), plasma concentration of SC5b-9 (middle panel) and 
serum concentration of Mannose-Binding Lectin (lower panel, Logarithmic scale) in South 
Asians with type 2 diabetes (SA DM+, n=168), South Asians without type 2 diabetes (SA DM-, 
n=100), and a control group of native non-diabetic Caucasians (CC, n=60). Horizontal bars 





group (median 558 (IQR 156-1680 µg/L versus 263 (IQR 133-613, P = 0.002). 
Non-diabetic South Asians had even higher MBL levels compared to Caucasians 
(1009 (IQR 239-1847) versus 263 (IQR 133-613), P < 0.001)
Diabetic versus non-diabetic South Asians
The diabetic South Asian group was older than the non-diabetic South Asian 
group (mean age 50.5 ± 11 versus 46 ± 7, P < 0.001). Sex distribution was not 
different (% male sex 46 versus 47, P = 0.97)
Both C3 and SC5b-9 levels were not different in diabetic South Asians compared 
to non-diabetic South Asians (875 µg ± 97 versus 854 ± 139, P = 0.184 and 0.355 
± 0.15 versus 0.362  ±  0.13, P = 0.708, respectively).  
Median MBL level was higher in non-diabetic South Asians compared to diabetic 
South Asians (1009 (IQR 239-1847) versus 476 (IQR 143-1536), P = 0.043). Genotype 
distribution was not different between non-diabetic and diabetic South Asians 
(A/A 63 versus 57%, A/O 31 versus 35%, O/O 6 versus 8%, P = 0.58)
Correlations of complement levels and clinical parameters in type 2 
diabetic South Asians
In the 168 type 2 diabetic South Asians, serum C3 levels correlated with age, 
sex, hsCRP, Body Mass Index, hip circumference, waist circumference and 
Cockroft-Gault creatinine clearance. SC5b-9 correlated only with sex and with 
fasting triglycerides. MBL level correlated with HbA1c and hip circumference 
but not with C3, SC5b-9, and hsCRP (table 2). 
Complement levels and albuminuria in diabetic South Asians
To investigate whether increased complement levels are associated with renal 
damage, complement levels in diabetic South Asians with albuminuria (n=53) 
were compared to diabetic South Asians without albuminuria (n=112). A SC5b-9 
level above the median was associated with the presence of albuminuria (sex 
adjusted OR 2.31, 95% CI 1.18-4.55, P = 0.015) whereas a C3 level above the 
median was not (OR 0.83, 95% CI 0.42-1.65, P = 0.60). 
MBL level above the median was not associated with albuminuria (OR 1.2, 95%CI 
0.63-2.13, P = 0.580). There was no statistically significant difference in median 
MBL level between diabetic subjects with and without albuminuria (528 µg/L 
(193-1308)versus 388 µg/L (130-1713), P = 0.740). Genotype distribution was also 
not different between diabetic South Asians with or without albuminuria (A/A 




Out of 168 type 2 diabetic subjects at baseline, 21 could not be traced and 13 
subjects refused to participate. Eighty-six subjects visited the out-patient clinic, 
31 subjects did not visit the out-patient clinic but medical information was 
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Age -0.285 < 0.001 0.139 0.078 -0.21 0.785
Sex 0.463 < 0.001 0.213 0.006 -0.141 0.071
Serum C3 1 0.097 0.247 -0.059 0.474
Plasma SC5b-9 0.97 0.247 1 0.027 0.731
Serum MBL# -0.059 0.474 0.027 0.731 1
High-sensitivity C-reactive 
protein#
0.479 < 0.001 0.006 0.936 0.042 0.596
Diabetes duration# -0.79 0.430 0.079 0.403 -0.055 0.562
HbA1c 0.049 0.554 0.046 0.564 0.165 0.034
Systolic blood pressure -0.061 0.463 0.078 0.325 -0.148 0.059
Diastolic blood pressure -0.033 0.689 -0.012 0.875 -0.133 0.090
Body Mass Index 0.264 0.001 0.079 0.319 -0.155 0.470
Waist circumference 0.180 0.029 0.009 0.913 -0.124 0.113
Hip circumference 0.218 0.008 0.038 0.627 -0.169 0.030
Waist-to-hip ratio -0.050 0.547 -0.037 0.641 0.042 0.594
HOMA-IR† 0.014 0.862 0.015 0.853 0.141 0.072
Total cholesterol 0.035 0.675 0.084 0.287 -0.108 0.170
Fasting triglycerides# 0.026 0.752 0.168 0.033 -0.081 0.304
Urinary albumin/creatinine 
ratio#
0.072 0.382 0.093 0.236 -0.001 0.986
Cockroft-Gault creatinine 
clearance
0.307 < 0.001 -0.016 0.843 -0.084 0.286
Not normally distributed parameters(#) were log-transformed
†HOMA-IR = Homeostatic Model Assessment for assessing insulin resistance
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obtained from the general practitioner, and 17 subjects had died (see below). 
The median duration of follow-up was 7.66 (IQR 7.48-8.10) years. Participants 
lost to follow-up did not differ in baseline characteristics from participants in 
whom follow-up data were available. Renal follow-up data were missing in 4 
subjects which were excluded from analysis with respect to renal endpoints.
Complement and cardiovascular events
During follow-up, 39 cardiovascular events occurred in 30 subjects (16 men, 14 
women): 3 sudden cardiac deaths, 2 fatal and 5 non-fatal myocardial infarction, 
13 percutaneous coronary interventions, 8 coronary artery bypass graft 
procedures,  2 fatal and 5 non-fatal strokes, 1 lower extremity amputation. 
Eleven of these 30 subjects had already experienced a cardiovascular event at 
baseline. Ten subjects died due to non-cardiovascular causes. Two of these 
subjects reached the primary end-point before they died, eight subjects did not 
and these were censored.
Baseline levels of complement did not predict cardiovascular events during 
follow-up (table 3). Serum C3 above the median was not associated with 
cardiovascular events (HR 1.28, 95% CI 0.58-2.84, P = 0.538). A SC5b-9 level above 
the median was also not associated with cardiovascular events (HR 1.79, 95% CI 
0.84-3.78, P = 0.132). In addition, complement levels were not associated with 
total cardiovascular events at the end of follow-up.  Baseline MBL levels were 
not associated with cardiovascular events (data not shown).  The association 
between MBL genotype and cardiovascular events is described in more detail 
in chapter 3 of this thesis.
Complement  and progressive renal failure
At the end of follow-up, 14 subjects had  progressive renal failure (11 subjects 
had a 50% increase in serum creatinine level, 1 initiated hemodialysis and 2 
had a kidney transplantation). 
A baseline SC5b-9 level above the median was associated with progressive renal 
failure (sex-adjusted HR 6.18, 95%CI 1.69-22.64, P = 0.006). After adjusting 
for MBL level, a SC5b-9 level above the median was still associated with 
progressive renal failure (HR 5.24, 95% CI 1.44-19.05, P = 0.012). After adjusting 
for age, sex, systolic blood pressure, HbA1c, fasting triglycerides, and urinary 
ACR, the association was statistically insignificant (multivariate HR 4.38, 95%CI 
0.88-22.0, P = 0.072). 
Serum C3 was not associated with progressive renal  failure. 
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Table 3    Association between clinical parameters, cardiovascular events 
and progressive renal failure
Cardiovascular events Progressive renal failure
Univariate 
HR
95% CI Univariate 
HR
95%CI
Serum C3 1.002 0.997-1.006 0.997 0.991-1.003
Serum C3 > median 1.28 0.58-2.84 0.66 0.235-1.861
Plasma SC5b-9 1.31 0.12-14.22 16.6 1.15-240
Plasma SC5b-9 > median 1.78 0.84-3.80 5.45 1.53-19.5
Serum MBL$ 1.18 0.68-2.05 3.19 1.23-8.23
Serum MBL > median 1.48 0.71-3.09 2.61 0.90-7.54
Age 1.02 0.99-1.06 1.037 0.993-1.083
Male sex 1.51 0.74-3.12 0.79 0.29-2.11
Diabetes duration 1.03 0.99-1.07 1.043 0.994-1.094
HbA1c 1.22 1.02-1.46 1.26 0.993-1.607
RR systolic 1.01 0.999-1.027 1.027 1.008-1.045
RR diastolic 1.02 0.989-1.058 1.029 0.983-1.077
Cockroft-Gault creatinin 
clearance
0.99 0.98-1.006 0.973 0.951-0.996
Urinary albumin/creatinine 
ratio$
1.97 1.36-2.83 4.44 2.61-7.54
Current or former smoking 1.27 0.61-2.62 1.04 0.384-2.814
Total cholesterol 1.20 0.81-1.80 1.28 0.74-2.21
Waist circumference 1.032 0.999-1.067 1.034 0.991-1.08
Hip circumference 0.96 0.94-099 1.012 0.957-1.070
Waist circumference > 
median
2.99 1.33-6.75 1.67 0.61-4.56
Waist-to-hip ratio > median 3.84 1.62-9.01 2.69 0.93-7.77
Body Mass Index 0.995 0.914-1.08 1.043 0.947-1.148
Fasting Triglycerides$ 1.84 0.37-9.19 7.08 1.25-40.13
Hing-sensitivity C-reactive 
protein$
1.37 0.60-3.13 1.53 0.52-4.51
Previous cardiovascular 
event




Serum SC5b-9 > median 4.38 0.88-22.0
Serum MBL$ 3.59 1.30-9.93
$ skewed-distributed variables are log-transformed
# included as covariates are age, sex, systolic blood pressure, ACR, triglycerides, HbA1c.
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Baseline MBL levels were significantly associated with progressive renal failure 
(univariate HR 3.19, 95%CI 1.23-8.23, P = 0.017), while MBL genotype was not. 
Adjustment for SC5b-9 did not change this association (HR 3.1, 95%CI 1.26-7.64, 
P = 0.014), nor did adjustment for hsCRP (HR 3.01, 95%CI 1.17-7.77, P = 0.023). In 
a multivariate analysis with sex, age, systolic blood pressure, hsCRP, HbA1c, 
fasting triglycerides, and urinary ACR as covariates, MBL levels remained 
associated with progressive renal failure (multivariate HR 3.59, 95%CI 1.30-9.93, 
P = 0.014) Baseline Cockroft-Gault creatinine clearance, urinary albumin/
creatinine ratio, systolic blood pressure and fasting triglycerides were also 
associated with progressive renal failure (table 3).
Discussion
South Asians have a high incidence of diabetes and subsequent vascular 
complications. Since traditional cardiovascular risk factors do not completely 
explain the increased incidence of vascular disease in South Asians,  other 
factors must be involved. There is increasing evidence that the complement 
system is involved in both macro- and micro-vascular complications [10-12]. 
Complement activation products are detected in atherosclerotic aortic plaques 
and in kidney biopsies and urine of subjects with diabetic nephropathy. In 
addition, experimental evidence supports a pathophysiologic role for SC5b-9 in 
the progression of atherosclerosis [27,28]
We hypothesized that  increased activity of the complement system might be 
involved in the enhanced rate of vascular complications in diabetic South 
Asians. In the cross-sectional study, we found that not only C3 – the central 
molecule in complement activation – is increased in South Asians compared to 
native Caucasians, but also SC5b-9 – the effector phase of complement 
activation- , supporting our hypothesis that complement activation  in South 
Asians is occurring at a higher level of activity. In addition, a high SC5b-9 level 
was associated with albuminuria, suggesting that complement activation is 
related to renal damage.
C3 levels were closely related to measures of adipose tissue mass (BMI, waist 
circumference, hip circumference). Indeed, C3 mRNA expression has been 
observed in –mainly omental- adipose tissue [29]. Adipocyte-derived C3 serves 
as a precursor of C3adesarg , also called Acylation Stimulating Protein (ASP) 
[30]. C3adesarg is generated through interaction of C3 with complement factor 
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B and the enzyme adipsin (also known as complement factor D). C3adesarg is 
inactive with respect to complement activation. Its main function is to increase 
triglyceride synthesis in fat-storing cells through stimulation of fatty acid 
incorporation. Increased C3 levels in South Asians thus might simply reflect 
increased central adipose tissue mass, although it is currently unknown to 
what extent adipocyte-derived C3 contributes to serum total C3 levels. 
Secondary mechanisms involving hepatic C3 production might also be 
involved.
A key question is whether an increased C3 level predisposes to enhanced 
complement activation. As C3 did not correlate with  SC5b-9, we did not find 
evidence that increased C3 levels result in enhanced complement activation, 
although enhanced complement activation at tissue level cannot be ruled out. 
In the prospective study, C3 level did not predict the occurrence of cardiovascular 
events, which is in contrast with observations in other populations [31]. However, 
the predictive value of a certain risk marker depends on the population being 
studied. Given the increased C3 level in the South Asian population, the inter-
individual predictive value with respect to cardiovascular disease might be 
attenuated, which has also been observed with other cardiovascular risk 
markers [32]. 
Baseline SC5b-9 levels also failed to predict cardiovascular events. Although 
this does not rule out a role for complement activation in atherosclerosis, 
plasma SC5b-9 level is not sensitive enough to serve as a risk marker for 
cardiovascular events. 
There is firm evidence that the complement system is involved in the progression 
of chronic renal failure. Experimental studies in various proteinuric models 
show complement activation on tubular cell brush border [33-37]. Inhibition of 
complement, either by administration of a complement inhibitor or by 
knock-out of complement components, results in attenuation of tubulointersti-
tial damage [33,36,37]. Complement activation also has been linked to the 
induction of renal fibrosis [38,39].
In our study, a high baseline SC5b-9 level was associated with both albuminuria 
and progressive renal failure. In contrast to the above mentioned experimental 
studies, which studied urinary complement  activation in overtly proteinuric 
animals, we measured blood levels of complement activation in subjects with 
various degrees of proteinuria. An association between blood levels of 
complement activation products and renal failure has not been reported 
previously. However, progressive renal damage has been linked to serum levels 
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of other inflammatory markers such as interleukines and Tumor Necrosis 
factor [40], suggesting that inflammation plays an important role in the 
pathogenesis of diabetic nephropathy. Whether increased SC5b-9 level in 
progressive renal failure reflects leakage of intra-renally formed SC5b-9, or 
whether it reflects systemically formed SC5b-9 due to generalized vascular 
inflammation is unknown.  
More recently, the MBL pathway of complement activation has come into focus 
as a contributor to diabetic vascular complications [10]. Cross-sectional studies 
found increased MBL levels in type 1 diabetic subjects compared to healthy 
controls [41]. In contrast, we found lower MBL levels in our type 2 diabetic 
South Asians compared to non-diabetic South Asians. This is probably explained 
by hormonal and metabolic differences between type 1 and type 2 diabetes, 
since MBL levels are lowered by insulin [42], and type 2 diabetes but not type 1 
diabetes is characterized by hyperinsulinemia.  
In type 1 diabetic Caucasians, MBL levels predict future development or 
progression of diabetic nephropathy [43, 44]. Experimental data show that MBL 
deficient streptozotocin-treated mice develop less diabetic nephropathy [45], 
which strongly suggests a pathophysiologcal role of MBL in the pathogenesis of 
diabetic nephropathy. Although earlier studies suggested that a high MBL 
genotype conferred an increased risk to diabetic nephropathy [10, 42], later 
studies with greater patient numbers could not confirm this [46]. In line with 
this, we found that high MBL levels at baseline were associated with progressive 
renal failure, whereas MBL genotype was not. High MBL levels thus may reflect 
an inflammatory state. In experimental ischemia/reperfusion models, high 
MBL levels exacerbate tissue damage [47].Oxidative stress induces a change on 
the cellular surface [48], which results in binding of MBL leading to enhanced 
complement mediated injury. Since in our study the association of MBL and 
progressive renal failure was independent of plasma SC5b-9, we found no 
evidence that high MBL levels result in increased complement activation, 
although enhanced complement activation at tissue-level cannot be ruled out. 
Whether increased MBL levels itself results in enhanced complement activation, 
or whether MBL levels are just a marker of inflammation thus remains to be 
resolved. 
In contrast to progressive renal failure, baseline MBL levels were not associated 
with cardiovascular events (see chapter 3 of this thesis). 
In conclusion, C3 levels are increased in South Asians compared to Caucasians, 
but do not predict future cardiovascular events or progressive renal failure. 
chapter 2
39
MBL levels and a high SC5b-9 were associated with progressive renal failure 
(micro-vascular disease) but not with cardiovascular events (macro-vascular 
disease), suggesting that complement activation  primarily affects the micro-
circulation. 
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South Asians have a high burden of type 2 diabetes and vascular complications. 
Vascular inflammation is considered central in the pathophysiology of athero-
sclerosis, and the complement system is thought to play an important role. 
Mannose-Binding Lectin (MBL), which activates the lectin pathway of 
complement activation, has been introduced as a risk marker of vascular 
damage. The present study explores the association of MBL levels, genotype and 
cardiovascular events in type 2 diabetic South Asians.
Research design and methods
We conducted a prospective observational study. A cohort consisting of 168 
type 2 diabetic South Asians was followed for a median duration of 7.66 years. 
At baseline, MBL levels and genotype were determined. The association with 
future cardiovascular events was assessed by Cox proportional hazard 
regression.
Results
During follow-up, 31 cardiovascular events occurred in 22 subjects (11 men, 11 
women). Compared to wild-type, the O/O genotype was significantly associated 
with the occurrence of cardiovascular events (hazard ratio 3.42, 95%CI 1.24-9.49, 
P = 0.018). However, MBL levels were not associated with the occurrence of 
cardiovascular events (hazard ratio 0.93, 95% CI 0.50-1.73).
Conclusion
In type 2 diabetic South Asians, the O/O MBL genotype is associated with 




South Asian immigrants in Western societies have a high burden of diabetes 
and vascular complications [1]. Traditional cardiovascular risk factors only 
partially explain this increased risk [2]. Hence other factors must be involved. 
Atherosclerosis, the pathologic substrate of macrovascular disease, is 
recognized to be an inflammatory process [3]. As a player in the inflammatory 
response, the complement system is thought to be involved in this vascular 
inflammation [4] Indeed, complement activation products have been 
demonstrated in atherosclerotic plaques [5].
The complement system can be activated via the classical, alternative or lectin 
pathway, which is activated when Mannose-Binding Lectin (MBL) binds to its 
target molecule. MBL binds carbohydrate moieties on microorganisms. However, 
endogenous MBL ligands, such as glycosylated immunoglobulins or cells 
exposed to oxidative stress, have also been identified [6]. MBL serum levels are 
primarily determined by 3 polymorphisms (B,C and D genotypes, commonly 
referred to as O-alleles) in the MBL gene (mbl2). Subjects with wild type MBL 
genotype (A/A) have the highest serum MBL levels, subjects with 1 variant allele 
(A/O) have intermediate levels and subjects with 2 variant alleles (O/O) have the 
lowest levels. In addition, polymorphisms in the promoter region influence the 
MBL level [7]. MBL is synthesized in the liver. Although intraindividual levels 
are relatively stable over time [8],  a two- to threefold increase occurs during 
acute phase reactions [9]. 
It has recently been suggested that MBL is involved in the pathophysiology of 
cardiovascular damage in high-risk populations [10]. In a group of type 1 
diabetic Caucasians, MBL levels were significantly higher in subjects with 
either a history of cardiovascular disease or diabetic nephropathy compared to 
subjects without these vascular complications [10]. In type 2 diabetic Caucasians 
high MBL levels were associated with increased mortality [11]. However, others 
found an association between low MBL levels and cardiovascular events [8,12]. 
Data on MBL in South Asians are lacking. 
We hypothesized that MBL might be involved in the high incidence of 
cardiovascular complications in type 2 diabetic South Asians. The current 
study aims to explore the association of MBL levels and genotype with 
cardiovascular complications in type 2 diabetic South Asians.
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Research design and methods
Design of the follow-up study
We conducted a prospective cohort study. All studied subjects were recruited from 
a previously published study [13]. The original study population comprised 465 
South Asians. At baseline, subjects that were not known with diabetes underwent 
a 75 g oral glucose tolerance test. Diabetes was diagnosed based on the ADA 2003 
criteria. Out of 465 subjects, 168 subjects had type 2 diabetes at baseline (122 
already known with diabetes, 46 newly diagnosed), and from these subjects 
follow-up data were collected. The study protocol was approved by the Institutional 
Medical Ethics Committee. All subjects provided informed consent.
Study-patients were followed up by letter and subsequently by phone. When 
subjects could not be traced by address or phone number in our database, 
general practitioners or participating family members were involved. 
Follow-up data consisted of medical history with regard to cardiovascular 
events. Subjects were sent a questionnaire and were invited for a visit to our 
out-patient clinic. During this visit the questionnaire was reviewed by the 
main investigator (M.A.S.). Subjects not willing to visit the out-patient clinic 
were asked permission to collect medical data from their general practitioner. 
For subjects who had died during the follow-up period, cause of death and 
cardiovascular history was retrieved from the general practitioner. All (self-)
reported events were verified by contacting the hospital in which the event had 
occurred.
Measurements at baseline
Laboratory measurements at baseline included lipids, creatinin, fasting 
glucose, urinary albumin/creatinine ratio, high-sensitivity C-reactive protein 
(hsCRP), and plasma SC5b-9, the soluble end product of complement activation. 
Lipids, creatinin, glucose and urinary albumin/creatinine ratio were measured 
according to standard methods. High-sensitivity C-reactive protein was 
measured with a fully automated Cobas Integra 800, according to the 
manufacturers proceedings (Roche, Almere, the Netherlands). The variation 
coefficients (VC) were below 3 %. Plasma levels of SC5b-9 were measured with 
an ELISA as described earlier [14].
MBL genotyping
DNA was isolated routinely from peripheral blood leucocytes. MBL single 
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nucleotide polymorphisms at codons 52, 54 and 57 of the mbl2 gene were typed 
by pyrosequencing. The detailed methodology has been published separately 
[15]. The MBL genotype of only wildtype allele carriers is designated as A/A and 
the presence of 1 or 2 variant alleles(s) (B, C, or D) is designated as A/O or O/O, 
respectively.
Serum MBL levels
At baseline, serum MBL levels were assessed by sandwich ELISA as described 
previously [16]. In brief, 96-well ELISA plates (Greiner, Frickenhausen, Germany) 
were coated with the monoclonal antibody 3E7 (mouse IgG1 anti-MBL at 2.5 µg/
ml), kindly provided by Dr. T. Fujita (Fuhushima, Japan). Serum samples were 
diluted 1/50 and 1/500 and incubated in the coated wells. MBL was detected 
with Dig-conjugated 3E7. Detection of binding of Dig-conjugated antibodies 
was performed using HRP-conjugated sheep anti-Dig Abs (Fab fragments, Roche, 
Mannheim, Germany). Enzyme activity was detected using 2,2'-azino-bis(3-eth-
ylbenzthiazoline-6-sulfonic acid) (Sigma Chemical Co., St. Louis, MO)). The 
optical density was measured at 415nm using a microplate biokinetics reader 
(EL312e; Biotek Instruments, Winooski, VT). A calibration line was produced 
using human serum from a healthy donor with a known concentration of MBL. 
Earlier studies indicated that this assay primarily detects wild-type MBL in 
serum and plasma and that there is a direct association with the MBL genotype 
and with MBL function [17]
Definitions and  endpoint
Cardiovascular events were defined as the occurrence of either a myocardial 
infarction, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary 
Artery Bypass Grafting (CABG), or sudden cardiac death. The latter was defined 
as a witnessed sudden circulatory arrest. The primary end-point was the time 
to the first cardiovascular event. 
Statistical analysis
Normally distributed variables are expressed as arithmetic mean ± 1 standard 
deviation. Skewed distributed variables are expressed as median with interquartile 
range.
Differences between groups were assessed with the independent samples t-test 
or the Mann-Whitney-U test for normally and  not-normally distributed 
variables, respectively. Comparison between multiple groups was performed 
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with analysis of variance. Correlations were assessed by using Pearson’s 
correlation and Spearman’s correlation as appropriate. Associations with 
cardiovascular events were assessed by Cox proportional hazard regression. 
The mean difference in log transformed MBL levels per MBL genotype (A/A, 
A/O,O/O) was calculated with linear regression. Hazard ratios (HR) were 
calculated by Cox regression analysis. The association between MBL genotype 
and cardiovascular events with the A/A genotype as reference genotype was 
calculated, and the HR for cardiovascular events per number of variant alleles. 
Subsequently, the association between MBL level and cardiovascular events 
was analyzed. In a Mendelian randomization approach following Fisher [18], 
we examined  the estimated causative effect of MBL level on cardiovascular 
events using the genotype as instrumental variable (figure 2). All tests were 
two-sided and the level of significance was  0.05.
All analyses were performed using SPSS Statistical Software Package (version 
17.0; SPSS, Chicago, IL)
Results
Baseline analysis
At baseline, serum MBL levels and MBL genotype were determined in 168 
diabetic subjects (122 already known with diabetes, 46 newly diagnosed). DNA 
was not available in 5 diabetic patients. Baseline characteristics of the study 
population are shown in table 1.
The median MBL level was 476  µg/L (IQR 143-1536  µg/L ). Genotype distribution 
in South Asians was the same as the reported genotype distribution in 
Caucasians [7] (table 2). MBL levels differed significantly per genotype (P < 
0.001): subjects with the A/A genotype had the highest MBL levels (median 1300 
µg/L, IQR 535-2258)  with the A/O genotype had intermediate MBL levels (median 
160 µg/L , IQR 75-295) and subjects with the O/O genotype had the lowest MBL 
levels (median 74  µg/L , IQR 38-101).
MBL levels correlated  weakly with Body Mass Index (r = -0.155, P = 0.014), HbA1c 
(r = 0.165, P = 0.034) and hip circumference (-0.169, P = 0.030) , but not with sex, 
age, blood pressure, high-sensitivity C-reactive protein (hsCRP), smoking status, 




Out of 168 type 2 diabetic subjects at baseline, 21 could not be traced and 13 
subjects refused to participate and thus were excluded from analysis. Eighty-six 
subjects visited the out-patient clinic, 31 subjects did not visit the out-patient 
clinic but medical information was retrieved from the general practitioner, 
and 17 subjects had died (see below). The median duration of follow-up was 7.66 
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Lost to follow-up 
(n=34)
P-value
Age (years) 50.7 ± 11.2 48.9 ± 11.2 0.392
% male sex 46 45 0.886
Diabetes duration (years) 7.0 (0-13) 5.0 (0-11) 0.519
HbA1c (%) 7.7 ± 1.8 7.7 ± 2.0 0.976
Systolic blood pressure (mm Hg) 138 ± 24 140 ± 27 0.638
Diastolic blood pressure (mm Hg) 84 ± 11 84 ± 11 0.937
Urinary albumin/creatinine ratio 
(mg/mmol)
1.0 (0.4-4.6) 1.0 (0.4-5.0) 0.991
High-sensitivity C-reactive protein 
(mg/L)
3.5 (1.8-8.0) 4.8 (1.7-8.4) 0.851
Cockroft-Gault creatinine clearance 
(ml/min)
86 ± 27 93 ± 20 0.205
Total cholesterol (mmol/L) 5.1 ± 1.0 5.0 ± 0.9 0.666
Fasting triglycerides (mmol/L) 1.59 (1.16-2.32) 1.46 (1.24-2.13) 0.869
HDL-cholesterol (mmol/L) 1.23 ± 0.3 1.28 ± 0.3 0.954
Ratio total cholesterol: HDL-
cholesterol
4.14 (3.45-5.05) 4.20 (3.10-5.0) 0.432
Body Mass Index 28.0 ± 4.7 28.4 ± 4.0 0.551
Waist circumference (cm) 96.4 ± 15.4 100 ± 10.1 0.154
Waist-to hip ratio 0.97 (0.93-1.03) 0.99 (0.95-1.04) 0.223
% previous cardiovascular event 14 11 0.663
% current or previous smoker 45 39 0.528
normally distributed variables are expressed as mean +/- SD, skewed distributed variables as 
median and interquartile range
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Table 2    median MBL level (interquartile range in brackets), genotype 
distribution and cardiovascular events
Median MBL level MBL genotype (%)
A/A A/O O/O
Cross sectional
South Asians (n=168)  476 µg/L (143-1536) 57 35 8* 
Caucasians [7] 60 36 4
Longitudinal
cardiovascular event † (n=22) 390 µg/L (77-1348) 50 20 30‡
no cardiovascular event (112) 466 µg/L (139-1545) 56 37 7
† Cardiovascular event: see text for definition
* P = 0.226 (% O/O in South Asians compared to Caucasians) 
‡  P = 0.005 (% O/O in subjects with cardiovascular event compared to subjects without 
cardiovascular event)
Table 3    MBL and risk for cardiovascular events
Hazard Ratio 95% CI
MBL genotype
A/A (n=74) 1
A/O (n=42) 0.65 0.20-2.07
O/O (n=13) 3.43 1.24-9.49
Combined A/O and O/O 1.26 0.52-3.04
Log MBL level (per log MBL increase)
Crude 0.93 0.50-1.73
Adjusteda 1.19 0.61-2.30
a  Adjusted for urinary albumin-to-creatinin ratio, log high sensitivity CRP, waist-to-hip ratio, 
smoking status, ratio total cholesterol: HDL-cholesterol, systolic blood pressure, age, sex, HbA1c, 
diabetes duration
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(IQR 7.48-8.10) years. Participants lost to follow-up did not differ in baseline 
characteristics from participants for whom follow-up data were available (table 1).
During follow-up, 31 cardiovascular events occurred in 22 subjects (11 men, 11 
women): 3 sudden cardiac deaths, 2 fatal and 5 non-fatal myocardial infarction, 
13 percutaneous coronary interventions, and 8 coronary artery bypass graft 
procedures. Eight of these 22 subjects had already experienced a cardiovascular 
event at baseline. 
Twelve subjects died due to non-cardiovascular causes. These patients were 
censored, none of them reached the primary end-point before dying.
Compared to the wild-type genotype, the O/O genotype was signifi cantly 
associated with the occurrence of a cardiovascular event (hazard ratio 3.42, 
95%CI 1.24-9.48, P = 0.018) (fi gure 1). Subjects with the O/O genotype did not 
differ in lipid parameters  or blood pressure compared to subjects with the A/A 
or A/O genotype. The A/O genotype was not associated with cardiovascular 
events (HR 0.65, 95% CI 0.20-2.07, P = 0.456). Cardiovascular events were also 
associated with a previous cardiovascular events (HR 4.3, 95% CI 1.2-10.3) and 
log urinary albumin/creatinine ratio (HR 1.58, 95% CI 1.0-2.48).
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Figure 1   
Unadjusted Kaplan-Meier survival curves according to MBL genotype (black line =  A/A (wild 
type) genotype, grey line = O/O genotype. The O/O genotype has a worse event-free survival 
compared to the A/A genotype (Log rank test P = 0.011).
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There was no statistically significant difference in baseline median MBL level 
between subjects experiencing a cardiovascular event during follow-up and 
subjects without a cardiovascular event (390 µg/L (IQR 77-1348  µg/L ) versus 466 
µg/L (IQR 139-1545  µg/L), P = 0.674). Log-transformed MBL levels were not 
associated with the occurrence of cardiovascular events (hazard ratio 0.93, 95% 
CI 0.50-1.73). MBL levels above the median were not associated with 
cardiovascular events (hazard ratio 0.94, 95% CI 0.40-2.20). Using other MBL 
cut-off levels also failed to show an association with cardiovascular events 
(data not shown). 
We used the MBL genotype as an instrumental variable to estimate the causal 
effect of MBL levels on cardiovascular events (Mendelian Randomization [19], 
figure 2). The rationale in Mendelian randomization is that, if an exposure is 
causally related to an outcome, a genetic variant, which is associated with the 
exposure, should have a similar relation to the outcome as the supposedly 
causal exposure itself. If the association with the outcome differs between 
genetic variant and genetic product, residual confounding or reverse causation 
(the outcome influencing the exposure) is present. 
Because of the small number in the O/O genotype and the relatively small 
difference in mean log MBL level between the A/O and O/O genotype,  we 
combined the A/O and the O/O genotype and compared this to the A/A genotype. 
Given the mean log MBL difference of 0.9 µg/L between the A/A and the combined 
A/O and O/O genotype and the HR for cardiovascular events of 1.26 for the 
combined A/O and O/O genotype with the A/A genotype as reference, the 
causative effect of MBL level on cardiovascular events was estimated, resulting 




The main finding of the present study is that in type 2 diabetic South Asians, 
the O/O MBL genotype was significantly associated with the occurrence of 
cardiovascular events compared to wild-type.
The association between low MBL genotype and cardiovascular events was 
previously reported in the Strong Heart Study [12]. This study included 
American Indians, which - like South Asians-  have a high burden of diabetes 
and subsequent vascular complications. A low MBL genotype was associated 
with a threefold increased risk for coronary heart disease. 
With respect to serum MBL levels and cardiovascular events, data are more 
controversial. Cross sectional studies found higher MBL levels in type 1 and 
type 2 diabetic Caucasians with a previous cardiovascular event compared to 
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Figure 2   
Calculation of the estimated causative hazard ratio of MBL levels on cardiovascular events, 
given the observed mean difference in log MBL level (between the A/A genotype and the 
combined A/O and O/O genotype) and the observed association between the genotype and 
cardiovascular events
Estimated HR per 1 log increase in MBL level:
1.26 (1/-0.90) = 0.77
Mean log MBL difference 
between A/A genotype 
and the combined A/O 
and O/O genoptype: -0.9
HR of non-wild-type 
versus wild-type: 1.26
MBL genotype
Serum MBL levels Cardiovascular events
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diabetic subjects without cardiovascular disease [10,11]. In non-diabetic 
Caucasian males but not in females, high MBL levels were associated with 
future cardiovascular events [20]. In type 2 diabetic Caucasians high MBL levels 
were associated with increased all cause mortality,  although data with respect 
to cardiovascular events were not reported [11]. In contrast, the prospective 
Reykjavik study found that in type 2 diabetic subjects low rather than high 
MBL levels were associated with increased incidence of myocardial infarction 
[8]. Recently, the Strong Heart Study provided data on MBL levels, confirming 
that low baseline MBL levels indeed were associated with future cardiovascular 
events [21]. In our study, MBL levels were not associated with future 
cardiovascular events.
A possible explanation for an association between low MBL levels and 
cardiovascular events might be a defective clearance of atherogenic particles. 
MBL binds  N-acetylglucosamine moieties, which are expressed on several 
lipoproteins and oxidized LDL [22], and this may facilitate their phagocytic 
clearance. This hypothesis is supported by a recently published study showing 
that MBL deficient subjects have impaired clearance of triglyceride-rich 
lipoproteins [23]. Additionally, MBL deficiency might influence the susceptibility 
and course of  infection with Chlamydia pneumoniae, which is associated with 
coronary artery disease [24]. On the other hand, MBL levels may increase in the 
setting of an inflammatory response [9]. Experimental studies show that in the 
setting of ischemia/reperfusion injury high MBL levels are detrimental rather 
than protective [25]. Oxidative stress induces a change on the cellular surface 
[26], which results in binding of MBL leading to enhanced complement mediated 
injury. However, since MBL levels were not correlated with plasma SC5b-9 levels 
in our study, we found no evidence that high MBL levels result in increased 
complement activation.
Summarizing the above, whereas most cross-sectional studies found an 
association between cardiovascular disease and high MBL levels, most prospective 
studies show an association between low MBL levels and cardiovascular events. 
In our study, low MBL genotype was associated with cardiovascular events and 
MBL genotype corresponds with MBL level. One would therefore expect low 
MBL levels  to be associated with cardiovascular events, which however was not 
the case in our study. MBL genotype probably is a more accurate estimate of 
cumulative MBL exposure  than a single serum MBL level. In addition, the 
contribution of MBL to vascular disease might differ according to the 
 pathophysiologic phase: early in the course low MBL levels might promote 
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 atherosclerosis, and once a vascular inflammatory response is established MBL 
levels might secondarily become increased and - perhaps - subsequently promote 
vascular inflammation.  A recent experimental study demonstrated local MBL 
synthesis in early atherosclerotic plaques [27], supporting the hypothesis that 
MBL levels might become increased due to atherogenesis. Based on the 
assumption of time-dependency of the association between MBL and 
cardiovascular disease, our single baseline sample might have been too late in 
the pathophysiologic course to detect the effect of low MBL level on 
cardiovascular outcome. In addition, variations of the MBL assay might 
contribute to the discordant findings between MBL genotype and MBL level. 
Furthermore, because we did not include the MBL promoter genotype, the gen-
otype-phenotype relation might be attenuated. Finally, at least theoretically, 
the association of low MBL genotype with cardiovascular events might be based 
on an association with other susceptibility genes for cardiovascular events.  
Noteworthy, although the O/O genotype was associated with cardiovascular 
events, the A/O genotype was not, although the difference in median MBL level 
between the O/O and A/O genotype was relatively small. The deleterious effect 
of low MBL level may only become apparent below a critical MBL value. 
To further assess the causative effect of low MBL levels on cardiovascular events, 
we estimated the effect of low MBL levels on cardiovascular events based on the 
relation between MBL genotype and cardiovascular events using a Mendelian 
Randomization approach [19]. In this approach, it is expected that the 
association between the genetic variant and the outcome (cardiovascular 
events) is equal to the association between exposure levels (MBL levels) and 
outcome. Differences between the expected and observed association are 
caused by residual confounding or reverse causation (that is, the disease 
influences the exposure levels). In our data, the expected HR per log MBL 
increase was 0.77, whereas the observed HR was 0.93. This suggests that, based 
on a single serum value,  the association of low MBL levels and cardiovascular 
events is attenuated. Reverse causation (MBL levels being increased because of 
vascular inflammation) might account for this.       
In conclusion, low MBL genotype is associated with cardiovascular events in 
type 2 diabetic South Asians, suggesting that MBL is involved in the pathogenesis 
of cardiovascular events. However, single serum MBL concentrations were  not 
associated with cardiovascular events and therefore a single MBL level is not 
a clinically useful risk marker for cardiovascular events in type 2 diabetic 
South Asians.
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Activation of filtered complement products on the brush border of the tubular 
epithelium is thought to be a key factor underlying proteinuria-induced tubu-
lointerstitial injury. However, the mechanism of tubular complement activation 
is still unclear. Recent studies on mechanisms of complement activation 
indicate a key role for properdin in the initiation of alternative pathway. We 
hypothesized that properdin serves as a focal point for complement activation 
on the tubulus.
We observed a strong staining for properdin on the luminal surface of the 
tubules in kidney biopsies from patients with proteinuric renal disease. In 
vitro experiments revealed dose-dependent binding of properdin to PTEC 
whereas no significant binding to endothelial cells was detected. Exposure of 
PTEC with normal human serum as a source of complement resulted in 
complement activation with deposition of C3 and generation of C5b-9. These 
effects were virtually absent with properdin deficient serum. Pre-incubation of 
PTEC with properdin before addition of properdin-depleted serum fully 
restored complement activation on the cells, strongly suggesting a key role for 
properdin in the activation of complement at the tubular surface.
In proteinuric renal disease, filtered properdin may bind to PTEC and act as a 
focal point for alternative pathway activation. We propose that this contribution 
of properdin is pivotal in tubular complement activation and subsequent 
damage. Interference with properdin binding to tubular cells may provide an 




Worldwide, the number of patients suffering from chronic kidney disease 
(CKD) is increasing dramatically [1]. The two most important factors contributing 
to the global rise in CKD are ageing of the population and the epidemic of type 
2 diabetes mellitus [2].  It has been well established now that in chronic kidney 
disease, regardless of the aetiology, proteinuria is a strong and independent 
predictor for the progression of chronic renal failure to end-stage renal disease 
(ESRD) [3,4]. Anti-proteinuric treatment is associated with preservation of renal 
function [5,6]. 
Several pathophysiologic mechanisms have been proposed to account for pro-
teinuria-induced tubulointerstitial injury. These include lysosomal rupture 
due to reabsorbed proteins, oxidative damage induced by transferrin 
reabsorption, and the stimulatory effects of various plasma proteins on the 
expression of proinflammatory and profibrotic mediators in renal tubular 
epithelial cells [7-9]. There is accumulating evidence for complement activation 
as a powerful mechanism underlying the progression of proteinuric renal 
disease. 
In the setting of proteinuria, plasma complement components may enter the 
tubular lumen [10]. If these complement components are then locally activated 
this would lead to cell activation and resulting tubular damage and interstitial 
fibrosis [11,12]. Indeed, proximal tubular epithelial cells (PTEC) activate serum 
complement in vitro via the alternative pathway [13,15]. Also in vivo, both in 
human chronic proteinuric disease and in experimental models, evidence of 
complement activation can be detected on the apical surface of the renal 
tubules [14,16,17]. The protective effect of C6 deficiency in the puromycin model 
of nephrotic syndrome, as well as in the remnant kidney model, provides 
further evidence for the role of complement in mediating tubulointerstitial 
injury [16,18]. Targeting complement inhibitory molecules to the proximal 
tubules in a rat model of proteinuric kidney disease protects against renal 
dysfunction [19]. 
However, the exact mechanism of the unique complement activating property 
of the proximal tubules has not yet been elucidated. Previous studies reported 
a role for local ammonium (NH
4
) in initiating alternative complement pathway 
activity [20,21]. We hypothesize that besides ammonium, other mechanisms 
might be involved in triggering tubular complement activation. 
The alternative pathway of complement is triggered by spontaneous hydrolysis 
complement activation by tubular cells is mediated by properdin binding
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of C3, which generates C3a and C3b. Cleavage of C3 results in the formation of 
a positive feedback loop to produce a rapid local response [22]. Properdin, 
discovered in 1954 by Pillemer et al.[23], is the only known positive regulator of 
the complement system and consists of dimers, trimers and tetramers arranged 
in a head-to-tail orientation[24,25]. Properdin binds to C3b and enhances 
complement activation by stabilizing the alternative pathway C3 convertase[26]. 
Lately, there has been renewed interest in properdin. It was shown that 
target-bound properdin may serve as a focal point for amplification of C3 
activation. Each subunit in the oligomer provides a ligand-binding site and the 
unoccupied ligand-binding sites can assemble the alternative pathway 
convertase on target surfaces [27,28]. It has recently been re-emphasized that 
properdin may act as a focal point in the activation of the alternative pathway 
of complement [27-30].  It was suggested already in 1954 that properdin might 
interact directly with cell surfaces [23,31].
In this study, we show that properdin binds to viable tubular epithelial cells 
and via this mechanism initiates complement activation.   
Materials and methods
Immunohistochemical staining
Frozen 4 µm tissue sections were used to determine the presence of properdin 
in cortical tissue of human kidneys. After the sections were fixed with acetone, 




 and 0.1% NaN
3
 for 
30 min at room temperature (RT). Then the slides were washed and subsequently 
blocked with phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA) 
and 5% heat-inactivated normal human serum for 45 min at RT. Next, sections 
were incubated with a polyclonal rabbit anti-human properdin antibody 
(Laboratory of Nephrology, Leiden, the Netherlands) in PBS, 1% BSA and 1% 
normal human serum in a humid atmosphere overnight at RT. After washing 
with PBS, antibody binding was detected with horseradish peroxidase 
(HRP)-labeled goat anti-rabbit Ig (DAKO, Glostrup, Denmark) in PBS, 1% BSA and 
1% normal human serum (60 min RT) followed by washing with PBS, incubation 
with Tyramide-fluorescein isothiocyanate in tyramide buffer (NEN™ Life 
Science Products, Boston, MA, USA; 20 min RT), washing with PBS, incubation 
with HRP-conjugated rabbit anti-fluorescein isothiocyanate (DAKO) for 60 min 
at RT, washing with PBS and development with DAB (Sigma, St Louis, MO, USA). 
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Sections were counterstained with hematoxylin (Merck, Darmstadt, Germany) 
and mounted with imsol (Klinipath, Duiven, The Netherlands).
Cell culture
The immortalized renal proximal tubular epithelial cell-line HK-2 was kindly 
provided by M. Ryan, University College Dublin, Ireland [32]. Cells were grown 
in serum-free DMEM/HAMF12 (Bio-Whittaker, Walkersville, MD) supplemented 
with 100 U/ml penicillin, 100 µg/ml streptomycin (Invitrogen, Breda, the 
Netherlands), insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 ng/ml), tri-io-
dothyronine (40 pg/ml), epidermal growth factor (10 ng/ml), hydrocortisone (36 
ng/ml, all purchased from Sigma). Primary human proximal tubular epithelial 
cells (PTEC) were isolated from pre-transplant biopsies or from kidneys not 
suitable for transplantation and cultured as described earlier (33). HUVEC were 
isolated from umbilical cords as described previously [34]. Cells were cultured 
on a matrix of fibronectin in M199 medium containing 20% heat-inactivated 
FCS, 100 U/ml penicillin, 100 ug/ml streptomycin, 50 ug/ml Bovine Pituitary 
Extract (all from Invitrogen) and 10 U/ml heparin (LEO Pharma B.V., Breda, the 
Netherlands). The cell lines ECRF-24, Jurkat, HL-60 and U937 were cultured as 
described earlier [35,36].
Isolation of properdin
Properdin was isolated from pooled human donor serum. First, a precipitation 
step was performed by dialyzing the serum against water containing 5 mM 
EDTA, pH 6.0. The resulting precipitate was dissolved in Veronal-buffered saline 
(2x VBS, 1.8 mM Na-5,5-diethylbarbital, 0.2 mM 5,5-diethylbarbituric acid, 145 
mM NaCl), dialyzed against 0.01 M NaAc containing 2mM EDTA, pH 6.0 and 
applied to a Sulphopropyl Sephadex C50 cation exchange colomn (Pharmacia 
Biotech, Uppsala, Sweden). Properdin was eluted from the column with a linear 
salt gradient. Properdin-containing fractions, as determined by enzyme-linked 
immunosorbent assay (ELISA), were pooled, concentrated, and subsequently 
applied to a Sephacryl S-300 gel filtration column (Pharmacia), after which 
properdin-containing fractions were pooled. In order to remove contaminating 
C1q from the preparation, the properdin-pool was dialyzed against PBS, 2 mM 
EDTA and further purified using human IgG coupled to a Biogel A5 column 
(Bio-Rad, Hercules, CA). Purity of the properdin preparation was confirmed by 
analysis on 10% non-reducing SDS-PAGE gel. A single band of 220 kDa was 
observed.




Normal human serum was depleted of properdin by immune adsorption using 
Biogel-coupled anti-human properdin monoclonal antibodies (a gift of State 
Serum Institute, Copenhagen, Denmark). The properdin-depleted serum 
showed normal classical and lectin pathway activity in hemolytic assay. 
C4-depleted serum, which lacks both classical and lectin pathway activity, was 
prepared by affinity adsorption using goat anti-human C4 IgG coupled to 
CNBr-activated Sepharose 4 Fast Flow (Amersham Bioscience Europe, 
Roosendaal, the Netherlands). After C4 depletion, the serum was free of C4 
antigen and classical pathway hemolytic activity could be restored fully by 
purified hemolytically active C4.
FACS analysis
Deposition of complement on cells was determined by flow cytometry. Properdin 
binding to the cells was visualized using a polyclonal rabbit anti-human 
properdin antibody followed by RPE-conjugated goat anti-rabbit IgG (Southern 
Biotechnology Associates, Birmingham, US). Deposition of C3, C5b-9, C1q, and 
MBL on the cells was detected using a mouse monoclonal anti-human C3 
antibody (RFK22, Laboratory of Nephrology, Leiden, the Netherlands), 
anti-human C5b-9 (mAb AE11, kindly provided by Dr. T.E. Mollnes, Nordland 
Central Hospital, Bodo, Norway), anti-human C1q (mAb 2204, kindly provided 
by Dr. C.E. Hack, Sanquin Research, Amsterdam) and anti-human MBL (mAb 
3E7, kindly provided by Dr. T. Fujita, Medical University School of Medicine, 
Fukushima, Japan) respectively, followed by RPE-conjugated polyclonal goat 
anti-mouse Ig (DAKO). All antibody incubations were performed on ice for 30 
min. Cell surface staining was assessed using a FACScalibur flow cytometer 
(Becton Dickinson, Mountain View, CA). Propidium iodide (1µg/ml, Molecular 
Probes, Leiden, the Netherlands) was used for exclusion of dead cells. 
Properdin binding and complement activation assays
For FACS experiments, cells were grown to confluence in 48-well tissue culture 
plates. HK-2 cells and HUVEC were exposed to 20% normal human serum 
diluted in serum-free DMEM/HAMF12 for 2 h at 37°C. C3, C5b-9, C1q, MBL and 
properdin were assessed on the cell surface by FACS analysis. Alternative 
pathway mediated complement activation by HK-2 was tested by incubating the 
cells with 20% normal human serum in the presence of 5 mM Mg EGTA. 
Properdin binding to HK-2, primary PTEC, HUVEC, ECRF-24, U937, HL-60 and 
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Jurkat was assessed by incubating the cells with purified human properdin (20 µg/
ml) diluted in serum-free DMEM/HAMF12 for 1 h at 37°C. Dose-dependent 
properdin binding to HK-2 and HUVEC was tested by incubating the cells with 
increasing concentrations of human properdin (10 to 40 µg/ml). The functional 
consequences of properdin binding were determined by incubating the cells 
with 5% properdin-depleted, normal human serum or C4-depleted human 
serum as a complement source, diluted in serum-free DMEM/HAMF12 culture 
medium, for 2 h at 37°C after pre-incubation with properdin. Following 
properdin and/or serum incubation, the cells were washed twice in PBS, 
harvested by scraping and resuspended in FACS-buffer (1% BSA and 0.02 % 
sodium azide in PBS) for FACS staining.
Results
Properdin is present on the tubular brush border in proteinuric 
kidneys
The presence of properdin on the brush border of the proximal tubules was 
determined in renal biopsies of three patients with membranous nephropathy 
and in pretransplant renal biopsies of three living related kidney donors. 
Properdin could be detected along the brush border of the tubules in diseased 
kidneys, whereas properdin was absent in the tubules of healthy kidney tissue 
(Figure 1). Since the presence of properdin on the tubular brush border of 
proteinuric kidneys does not distinguish where in the cascade of complement 
activation properdin comes in, we proceeded to in vitro studies to determine 
whether properdin is an initiating factor in tubular complement activation.
Complement activation by HK-2 cells
Incubation of Human Kidney-2 (HK-2) cells with normal human serum resulted 
in fixation of complement products on the cell surface. C3, C5b-9 and properdin, 
but not C1q and mannan-binding lectin (MBL) could be detected (Figure 2a). 
The complement system was activated on the cell surface via the alternative 
pathway since deposition of C3 and C5b-9 was unaffected by Mg EGTA, which 
interferes with the classical and lectin pathway of complement by chelating 
calcium (Figure 2b). In contrast, complement fixation was completely blocked 
by EDTA, which inhibits all three pathways of complement activation. C3 and 
C5b-9 deposition was also detected on HK-2 cells after exposure to C4-depleted 
complement activation by tubular cells is mediated by properdin binding
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human serum, which excludes involvement of the classical or lectin pathway 
(Figure 2c). To assure that complement activation was localized to the apical 
surface, serum incubations were performed on cells that were grown to 
confluence in a tissue culture plate. Human umbilical vein endothelial cells 
(HUVEC) were used as a control. No complement deposition was observed on 
these cells after treatment with normal human serum.   
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Figure 1    Properdin staining on the tubular brush border in proteinuric 
kidneys
Cryosections of (a and b) a renal biopsy of a patient with membranous nephropathy and (c and 
d) a pretransplant biopsy of a healthy donor were stained immunohistochemically for 
properdin. (a and c) Original magnifications were either × 100 or (b and d) × 250. Pictures are 
representative for three patients with membranous nephropathy and three healthy kidneys 
donors. 
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Figure 2    Complement activation by HK-2 cells
(a) HK-2 cells were incubated with 20% normal human serum (NHS). C3, C5b-9, C1q, mannan- 
binding lectin (MBL) and properdin binding (filled histograms) were assessed on the cells using 
the mAbs RFK22, AE11, 2204, 3E7 and a polyclonal rabbit anti-properdin antibody, respectively. 
Open histograms show staining on cells that were not exposed to serum. (b) C3 deposition was 
assessed on HK-2 cells after incubation with 20% human serum in the presence or absence of 
5mM Mg EGTA or 10 mM EDTA. Results are expressed as the mean fluorescence intensity, MFI. 
(c) C3 and C5b-9 deposition on HK-2 cells after exposure to 20% C4-depleted human serum.
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Binding of properdin to HK-2 cells
We then questioned whether properdin could bind to tubular cells prior to the 
activation of complement and the deposition of its known ligand C3b. In order 
to study binding of properdin to the cell surface, confl uent cells in a tissue 
culture plate were incubated with purifi ed human properdin at a concentration 
of 20 µg/ml. Properdin binding was analysed by fl ow cytometry. Only cells 
which were negative for propidium iodide staining were analysed in order to 
exclude properdin binding to dead cells. As shown in Figure 3a, strong binding 
of properdin to viable HK-2 cells was detected, whereas no signifi cant binding 
was shown on HUVEC. As a negative control, the fl uorescence intensity of cells 
incubated with detection antibody only, i.e., without pre-incubation with 
properdin, is shown. Properdin binds to viable HK-2 cells in a dose-dependent 
manner (Figure 3b). The cell lines HL-60, U937 (monocytes), Jurkat (T-cell 
leukaemia) and ECRF-24 (immortalized HUVEC) were all negative for properdin 
binding (Figure 3c).
Properdin binding is a focal point for alternative pathway activation 
on HK-2 cells
Next, we investigated whether properdin, after binding to the tubular surface, 
acts as a focal point for local amplifi cation of the alternative pathway of 
complement. To demonstrate properdin-dependent complement activation, 
deposition of C3 and C5b-9 was assessed on HK-2 cells and HUVEC incubated 
with properdin-defi cient normal human serum, with and without 
pre-incubation of the cells with purifi ed properdin. HK-2 cells incubated with 
properdin-depleted serum show a strongly reduced C3 deposition compared to 
cells exposed to normal human serum. This is accompanied by a strong 
reduction of C5b-9 deposition. Complement activation was restored completely 
on cells that had been pre-incubated with properdin, prior to exposure to prop-
erdin-defi cient serum (Figure 4a and b). HUVEC showed no signifi cant 
complement activation, both with and without pre-incubation with purifi ed 
properdin. This indicates that properdin, bound to the cellular surface of HK-2, 
initiates and targets the amplifi cation of the complement cascade to the surface 
of tubular cells. 
To confi rm that complement activation on HK-2 is properdin-dependent, cells 
were pre-exposed to different concentrations of purifi ed properdin, ranging 
from 2,5 to 40 µg/ml, before incubation with 5% normal human serum. 
Properdin was shown to increase the deposition of both C3 and C5b-9 on HK-2 
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in a dose-dependent way (Figure 5a). Similar dose-dependent effects were 
detected when increasing concentrations of properdin were added prior to 
incubation with C4-depleted human serum (Figure 5b). 
complement activation by tubular cells is mediated by properdin binding
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Figure 3    Properdin binding to HK-2 cells
(a) HK-2 cells and human umbilical vein endothelial cells (HUVEC) were incubated with 20 µg/
ml purifi ed human properdin. Binding of properdin (fi lled histograms) was detected with a 
polyclonal rabbit anti-human properdin antibody followed by goat anti-rabbit conjugated with 
PE. As a negative control, staining with both primary and secondary antibody was performed 
on cells that were not exposed to properdin (open histograms). (b) Dose-dependent binding of 
properdin to HK-2 and HUVEC is shown as the mean fl uorescence intensity (MFI). Data are 
representative for two individual experiments.  (c) Binding of properdin (shown as the mean 
fl uorescence intensity, MFI) to the cell lines Jurkat, HL-60, U937, ECRF-24, HUVEC and HK-2. 
Data are expressed as the mean ± SD of three independent experiments.
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Properdin binding and complement activation on PTEC
In order to test whether the PTEC cell line HK-2 is representative for primary 
PTEC lines, properdin binding and properdin-dependent complement activation 
was assessed on primary PTEC cultures. As shown in Figure 6a, properdin 
binding on PTEC is comparable to HK-2 (Figure 3a). The six tested PTEC cell 
lines showed variability in properdin binding (Figure 6b). None of the three 
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Figure 4    Properdin-dependent complement activation
HK-2 cells and human umbilical vein endothelial cells (HUVEC) were pre-incubated with 
properdin (P, 20 µg/ml), washed and subsequently exposed to 5% properdin-depleted human 
serum (Pds). (a) C3 and (b) C5b-9 deposition (shown as the mean fl uorescence intensity, MFI) was 
detected on the cells using the mAbs RFK22 and AE11, respectively. The results are expressed as 





HUVEC cell lines showed significant binding of properdin. However, the extent 
of properdin binding to PTEC was strongly correlated with the level of C3 
deposition on these cells, r = 0.96 / p = 0.002 (Figure 6c).
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Figure 5    Dose-dependent effect of properdin on complement deposition
HK-2 cells were pre-incubated with increasing concentrations of human properdin. After 
extensive washing, cells were exposed to (a) 5% normal human serum or (b) 5% C4-depleted 
human serum. Complement deposition (expressed as the mean fluorescence intensity, MFI) was 
assessed by flow cytometry using mAbs RFK22 and AE11 for staining of C3 and C5b-9, 





Figure 6    Properdin-mediated complement fixation on primary PTEC
(a) Primary proximal tubular epithelial cell (PTEC) lines were analysed for properdin binding 
(filled histogram) by flow cytometry after incubation with 20 µg/ml purified human properdin. The 
open histogram shows staining on cells that were not incubated with properdin. (b) Binding of 
properdin to different PTEC and human umbilical vein endothelial cell (HUVEC) lines. Properdin 
binding is expressed as the mean fluorescence intensity (MFI). The background fluorescence 
(primary and secondary antibody without properdin pre-incubation) is subtracted for each cell 
line individually. (c) Properdin binding and resulting properdin-dependent complement activation 
was tested by incubating the cells with 5% properdin-depleted human serum (Pds) after pre-exposure 
to 20 µg/ml purified properdin. Properdin binding and C3 deposition is shown as the mean 
fluorescence intensity (MFI). The association between properdin binding and the level of C3 
deposition was analysed by calculating the Pearson correlation coefficient.







In the present study, we show that properdin binds to the surface of viable 
PTEC. Properdin binding serves as a focal point for local amplification of the 
alternative pathway of complement on PTEC and explains the complement 
activating capacity of these cells. 
It has been known for a long time that the apical surface of human proximal 
tubular epithelial cells activates the complement system in vitro and in vivo via 
the alternative pathway [13,14]. In patients suffering from chronic proteinuric 
renal disease, deposition of complement along the tubular brush border is 
accompanied by tubulointerstitial injury and progressive loss of renal function. 
Experimental models of non-selective proteinuria provide further evidence for 
the role of tubular complement activation in mediating tubulointerstitial 
injury [17,19]. C6 deficiency protects kidney function in the remnant kidney 
model as well as in the puromycin-induced model of nephrotic syndrome 
[16,18]. 
Although in physiological conditions complement components are not filtered 
through the glomerular barrier, several studies demonstrated the presence of 
complement activation products (CAP) in the urine of patients with nephrotic 
syndrome due to a variety of causes [10,37-39]. These studies showed a positive 
correlation between tubular C3 fixation and the excretion of complement 
components as well as complement activation products (including iC3b, Bb and 
C5b-9) in the urine. Interestingly, the level of urinary CAP excretion was 
significantly decreased after two weeks of oral sodiumbicarbonate 
administration (38;40). The protective effect of bicarbonate was suggested to be 
due to lowering of the tubular ammonium concentration but may also be 
explained by a direct effect of increasing the urinary pH [41].
Despite extensive research, the mechanism of complement activation on the 
tubular brush border has not yet been fully elucidated. It was suggested that 
local ammonium reacts biochemically with the thioester of C3 and thereby 
acts as a C3 activator [20,21]. However, the addition of ammonium to serum 
only resulted in 15% increase in lysis of rabbit erythrocytes. This weak effect of 
ammonium on complement activation was only present in the lower 
concentration range. At higher concentrations, ammonium inhibited the 
alternative pathway. Recently, the activation of complement in proximal tubule 
cells was studied using proteinuric urine [41]. Increasing concentrations of 
ammonium resulted in an inhibition of complement activation. Ammonium 
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excretion obviously does not fully explain the propensity of the renal tubule 
cells to activate the complement system. 
Others have suggested that the lack of complement regulatory molecules on 
the apical surface of PTEC may explain the capacity of these cells to activate 
complement. Indeed, CD46 (membrane cofactor protein, MCP) only seems to be 
expressed on the basolateral surface of PTEC and CD55 (decay accelerating 
factor, DAF) could not be detected at all [42,43]. On the other hand CD59 is 
expressed abundantly on PTEC and surface expression of both CD46 and CD55 
were detected on a PTEC cell line [44].
We suggest that the unique properdin binding capacity of PTEC critically 
controls the tubular complement activation in proteinuric states. In 1974, Sato 
et al. described that the damaging effect of intraluminally perfused normal rat 
serum on the rat kidney proximal tubule could be abolished by pre-incubating 
the serum with a brush border membrane fraction [45]. Possibly the effect of 
pre-inbcubation with the brush border membrane fraction is explained by its 
capacity to absorb properdin.
It was recently re-emphasized that properdin, the only known naturally 
occurring positive regulator of complement, can act as a focal point for 
alternative pathway amplification [27,28], thereby directing complement 
activation to the cell surface of apoptotic and necrotic cells [29,46]. Several 
decades before, Pillemer et al. suggested that properdin might also interact 
directly with target surfaces [23,31] Likewise, we hypothesized that properdin 
might be the activator of the alternative pathway on the tubular brush border 
by interacting with molecules present on the cell membrane.
At the moment, the ligand on PTEC that mediates the interaction with properdin 
has not yet been identified. Properdin has been shown to bind to surface-bound 
C3b via one of its subunits followed by the assembly of the alternative pathway 
convertase at the ligand-binding sites of the adjoining subunits [27]. At the 
moment we can not fully exclude that properdin binds to PTEC via cell-bound 
C3b that is derived from endogenously produced and activated C3. Although C3b 
is undetectable by flow cytometry on PTEC, it might be present below the 
detection limit. On the other hand, it seems unlikely that significant amounts of 
C3b are present on quiescent cells. Recent data suggest that properdin also binds 
to the glycosphingolipid sulfatide [47]. The presence of sulfatide on the brush 
border of the tubules has been demonstrated in the rat kidney [48]. It is likely 
that these molecules are also expressed on the tubules in the human kidney, 
where they may mediate properdin binding to PTEC. 
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The mechanism by which a sublytic dose of C5b-9 on PTEC leads to tubular 
damage and subsequent tubulointerstitial fibrosis is thought to be via activation 
of proinflammatory and fibrogenic pathways [4]. Insertion of C5b-9 into the 
cell membrane of PTEC results in the production of proinflammatory cytokines 
and collagen synthesis. Interestingly, PTEC have been shown to synthesize a 
functional alternative pathway of complement, which is capable of activating 
the cells [49]. This intratubular complement activation is tightly regulated and 
probably plays a role in protecting the kidney from urinary tract infections. 
Since the apical tubular surface does not come into contact with high 
concentrations of plasma proteins in normal physiology, protection against 
circulating complement is of less importance compared to circulating cells 
and the endothelium. However, in proteinuric renal disease, the tubules are 
exposed to filtered complement components. In these circumstances, the 
complement activating capacity of PTEC is harmful, especially since the apical 
surface has virtually no protection against complement attack [42].
Our data show that properdin binding to the brush border is the rate-limiting 
step in tubular complement activation. Targeting the interaction between 
properdin and the tubular brush border might be a therapeutic approach for 
controlling tubulointerstitial injury, thereby preventing progressive loss of 
kidney function in patients with chronic proteinuric renal disease. 
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Proteinuria predicts progressive renal failure. Next to being a progression 
marker, non-selective proteinuria itself is thought to be toxic to the tubuloint-
erstitium. In proteinuric states, activation of filtered or locally produced 
complement is toxic for renal tubular cells and likely contributes to the 
progression of renal failure. Recent experimental evidence suggests an 
important role for properdin in promoting intrarenal complement activation. 
We measured properdin in proteinuric urine and assessed its relation with 
urinary SC5b-9 levels, the soluble form of the effector phase of complement 
activation.
Methods
Seventy patients with renal disease of different origin but all with a protein 
excretion of at least 1 gram/day were studied. Urinary properdin and SC5b-9 
levels were measured using an ELISA technique.
Results
Properdin was detectable in the urine of 37 patients (53%). These subjects had 
higher urinary SC5b-9 levels (median 0.50 U/ml (IQR 0.13-1.81) versus 0.049 U/
ml (IQR 0.024-0.089), P<0.001). When adjusted for proteinuria and renal 
function, properdin excretion was strongly associated with increased urinary 
SC5b-9 levels (Odds Ratio 16.2, 95%CI 3.6-74.4) Properdin excretion was 
associated with worse renal function.
Conclusion
Our results suggest that urinary properdin excretion enhances intrarenal 
complement activation and thus may contribute to the progression of renal 




Proteinuria is a prognostic marker in renal disease. Besides being a marker of 
renal damage, non-selective proteinuria is thought to be toxic to the tubuloint-
erstitium [1-4]. Activation of filtered or locally produced complement 
components is likely involved in tubulotoxicity of proteinuria [5;6]. Complement 
activation products indeed are detectable in urine of patients with different 
proteinuric renal disease [7-9]. 
The complement cascade is activated by binding of recognition molecules to 
their respective target. Immunoglobulins and Mannan Binding Lectin (MBL) 
are the recognition molecules of the classical and lectin pathway, respectively. 
The alternative pathway is characterized by spontaneously occurring low-grade 
complement activation [10], and renal proximal tubular cells have long been 
known to activate complement via the alternative pathway [11-14]. Properdin 
enhances alternative pathway complement activation by stabilizing the 
alternative pathway C3 convertase [15]. More recent data suggest that properdin 
also acts as a recognition molecule of the alternative pathway [16-19]. 
We recently demonstrated a pivotal role for properdin as a mediator of 
complement activation by proximal tubular epithelial cells (PTECs) [20]. After 
incubation with normal human serum, complement activation on PTECs was 
observed, whereas complement activation was absent when PTECs were 
incubated with properdin deficient serum. Pre-incubation of PTECs with purified 
properdin before addition of properdin-deficient serum restored the complement 
activating capacity by PTECs in a dose-dependent manner, indicating that 
properdin acts as a focal point for complement activation. However, data 
regarding involvement of properdin in proteinuric renal disease are lacking.
We therefore studied the excretion of properdin in proteinuric kidney disease 
and assessed its association with urinary excretion of SC5b-9 and renal damage. 
We show that properdin is present in proteinuric urine, and that its presence 
is associated with increased SC5b-9 excretion and worse renal function.
Subjects & methods
Between february 2006 and november 2007 all adult patients attending the 
renal out-patient clinic with a protein excretion of at least 1 gram per day 
during the last visit were included. All patients gave informed consent. Ten ml 
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of freshly voided urine (to which 400 µl of a protease inhibitor solution (25 x 
concentrated solution of Complete Protease Inhibition, Roche, Mannheim, 
Germany) was added), 10 ml of EDTA blood and 10 ml of serum were collected 
and immediately put in ice. After 10 minutes centrifugation at 2500 rounds per 
minute at 4º Celsius, aliquots of the samples were stored at -80º Celsius for later 
complement measurements. Serum creatinin was measured by Jaffé’s method 
[21]. Urinary albumin was measured by an immunoturbidimetric assay [22], 
and total protein was measured by a colorimetric method [23].
To secure that at the time of inclusion the patient indeed was excreting at least 
1 gram of protein per day, the actual urinary protein excretion was calculated 
as follows: 
creatinin (mmol/24 hour) in 24 h urine collection 
creatinin (mmol/L) in aliquot) 
x  total protein (gr/L) in aliquot 
When calculated actual protein excretion was less than 1 gram per day, the 
patient was excluded from further analysis. 
Quantification of SC5b-9
SC5b-9 levels were assessed by sandwich ELISA. In brief, 96-well ELISA plates 
(Nunc Bioscience, Belgium) were coated with the monoclonal antibody aE11 
(mouse IgG2a anti-C5b-9 3mg/ml), which was kindly provided by dr. T. Mollnes 
and described in detail previously [24]. Plasma and urine samples were diluted 
1/5 and 1/20 and incubated in the coated wells. Bound SC5b-9 was detected 
with a biotin labeled monoclonal anti C6 antibody (9C4), followed by detection 
with streptavidin-poly horse radish peroxidase (Sanquin, Amsterdam, The 
Netherlands). Enzyme activity was detected using 2,2’-azino-bis(3-ethylbenz-
thiazoline-6-sulfonic acid) (Sigma Chemical Co., St. Louis, MO). All assays were 
performed on ice. The optical density was measured at 415nm using a microplate 
biokinetics reader (EL312e; Biotek Instruments, Winooski, VT). A calibration 
line was produced using zymosan activated serum with a known concentration 
of SC5b-9 of 1000 U/ml
Quantification of properdin
Properdin levels were assessed by a previously described sandwich ELISA with 
a detection limit of 1.5 ng/ml. [25]. In brief, 96-well ELISA plates (Nunc Bioscience, 
Belgium) were coated with a polyclonal rabbit anti-human properdin solution 
generated by immunizing a rabbit with purified human properdin. Serum 
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(diluted 1:1000) and urine (diluted 1:5) were incubated in the coated wells. 
Bound properdin was detected with digotonin labeled rabbit anti human 
properdin, followed by detection with anti digotonin conjugated with horse 
radish peroxidase (Sanquin, Amsterdam, The Netherlands). Enzyme activity 
was detected using 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma 
Chemical Co., St. Louis, MO). The optical density was measured at 415nm using 
a microplate biokinetics reader (EL312e; Biotek Instruments, Winooski, VT). A 
calibration line was produced using a normal human serum-properdin-stan-
dard with a known properdin-concentration of 20 µg/ml.
Statistical analysis
Normally distributed variables are expressed as mean ± standard deviation and 
skewed distributed variables as median and interquartile range. Differences 
between groups are assessed by Student’s t-test or Mann-Whitney-U test as 
appropriate. Spearman’s correlation was determined for skewed distributed 
variables. Associations between properdinuria and urinary SC5b-9 were 
assessed with logistic regression. All tests were two-sided and the level of 
significance was set at 0.05. All analyses were performed using SPSS for 
windows, version 15.0.
Results
Seventy patients were suitable for analysis. In 5 of these patients, data on 24 
hour protein excretion were missing, but the total protein to creatinin ratio 
was > 0.33 gr/mmol, confirming that the actual protein excretion is > 1 gram/24 
hours and therefore they were also included.
The mean age of the patient population was 55 ± 16 years. The median 
endogenous creatinin clearance was 39 ml/min (IQR 21-75) and the median 
actual calculated protein excretion was 3.4 gr/24 hours (IQR 2.1-6.0). There 
were 18 type 2 and 9 type 1 diabetic subjects suffering from diabetic 
nephropathy, as diagnosed by a characteristic course of proteinuria and renal 
deterioration in the presence of diabetic retinopathy. Twenty seven patients 
had glomerular disease (7 membranous nephropathy, 2 IgA nephropathy, 7 
lupus nephritis, 2 secondary Focal Segmental Glomerulosclerosis, 2 ANCA 
associated vasculitis, 3 Membranoprolipherative glomerulonephritis, 2 minimal 
change nephropathy, 2 Monoclonal Immunoglobulin Deposition Disease / 
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amyloidosis). In all these patients diagnosis was based on renal biopsy. Sixteen 
subjects were categorized as “other”: they did not have a renal biopsy and only 
a presumptive diagnosis was made, mostly nephrosclerosis.
The characteristics of the study population are summarized in table 1.
In 37 patients (53%), properdin (up to 0.39 µg/ml) was detected in the urine. 
Properdin was not detectable in the urine of 25 healthy subjects without 
proteinuria. Compared to patients without detectable urinary properdin 
excretion, patients with urinary properdin had significantly higher urinary 
SC5b-9 levels (median 0.50 U/ml (IQR 0.13-1.81) versus 0.049 U/ml (IQR 
0.024-0.089), P<0.001) (Figure 1a). By logistic regression analysis it was 
demonstrated that the presence of properdinuria was associated with urinary 
SC5b-9 levels above the median (OR 16.3, 95%CI 5.0-53.2). When only subjects 
with properdinuria were considered, urinary properdin and SC5b-9 levels were 
correlated (Spearman’s ρ 0.338, P=0.041)
Compared to subjects without properdinuria, subjects with properdinuria also 
had more proteinuria (urinary albumin concentration 2.48 gr/L(IQR 1.2-4.0) 
versus 1.0 gr/L (IQR 0.6-1.9), P<0.001) and worse renal function (endogenous 
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Age (years) 55 ±16 56 ± 14 51 ± 18 59 ± 4


























% of subjects with properdinuria 53% 74% 44% 31%
Normally distributed variables are represented as mean ± standard deviation, skewed 
distributed variables are represented as median (interquartile range in brackets)
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Figure 1   
Subjects with properdinuria have significantly higher median levels of urinary SC5b-9  
(figure 1a), a higher degree of proteinuria (figure 1b) and worse renal function (figure 1c) 





creatinin clearance 26 ml/min (IQR 15-50) versus 51 ml/min (IQR 38-90), 
P<0.001) (figure 1b and 1c, respectively). However, the presence of properdinuria 
remained strongly associated with urinary SC5b-9 excretion above the median 
when adjusted for urinary albumin concentration and renal function in a 
multivariate analysis (OR 16.2, 95%CI 3.6-74.4).
Discussion
In this study, we show that properdin is present in proteinuric urine, and that 
the presence of urinary properdin is associated with increased SC5b-9 excretion 
and worse renal function.
Intratubular complement activation is thought to be an important pathway of 
toxicity to the tubulointerstitium [5;6]. Experimental studies in various 
proteinuric models show complement activation on tubular cell brush border 
[26-29]. Inhibition of complement, either by administration of a complement 
inhibitor or by knock-out of complement components, results in attenuation of 
tubulointerstitial damage [26;29;30]. In vitro studies show alternative pathway 
mediated complement activation on cultured proximal tubular cells [11-14], and 
complement activation has been linked to the induction of renal fibrosis [31;32].
The complement cascade is activated by binding of recognition molecules to 
their respective target. Immunoglobulins and Mannan Binding Lectin (MBL) 
are the recognition molecules of the classical and lectin pathway, respectively. 
The alternative pathway is characterized by spontaneously occurring low-grade 
complement activation [10], but also serves as an important amplification loop 
for the classical and lectin pathway [15;33]. Properdin acts as a promoter of 
complement activation by stabilizing the alternative pathway C3 convertase 
[15], but more recent data suggest that properdin also acts as a recognition 
molecule of the alternative pathway [16-19]. Properdin is mainly synthesized by 
inflammatory cells like monocytes and leucocytes which release their properdin- 
containing granules upon activation [34,35].
Although the capacity of cultured tubular cells to activate the alternative 
complement pathway has long been known, the exact mechanism has not been 
determined. We recently demonstrated a pivotal role for properdin in 
complement activation by cultured proximal tubular cells [20]. In the present 
cross sectional study, properdinuria was associated with higher urinary SC5b-9 
levels, suggesting that properdin is an important determinant in intratubular 
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complement activation. Interestingly, our results show that the association of 
properdinuria with urinary SC5b-9 levels was independent of the degree of 
proteinuria. Properdinuria was also associated with worse renal function 
suggesting a role for properdin in proteinuria mediated renal damage.
There are several possible explanations for the observed association of 
properdinuria and renal dysfunction. Properdin, filtered together with other 
complement components in glomerular protein leakage, may initially bind to 
tubular cells with subsequent activation of the alternative pathway. This 
tubular complement activation would then lead to tubulointertistial damage 
induced by complement activation products like C3a, C5a and C5b-9 [31;32]. 
Alternatively, as properdin is mainly synthesized by inflammatory cells such 
as polymorphonuclear cells, properdinuria might be related to intrarenal 
recruitment of inflammatory cells, that has been shown to be correlated with 
renal dysfunction [36]. Diminished tubular properdin reabsorption reflecting 
tubular damage might also contribute to the presence of urinary properdin 
and its association with worse renal function.
In serum, properdin is present as dimers, trimers, and tetramers, but not as 
monomers [37]. Discrimination between these forms might help in determining 
its main source (multimeric properdin from blood, monomeric properdin from 
intrarenal inflammatory cells). However, the polyclonal anti-properdin 
antibody we used recognizes all forms of properdin, so we can only speculate 
about its source. 
It is noteworthy that properdinuria was frequent in our diabetic subjects. An 
increasing body of evidence suggests that in diabetic nephropathy- although 
traditionally considered a non-immune mediated disease- the immune system 
actually is involved, at least in the progression towards renal failure. In the 
present study as in previous ones, patients with diabetic nephropathy have 
relatively high levels of urinary SC5b-9 [7;8], indicating the contribution of 
complement mediated damage. 
We are aware of the limitations of our study: first, because of the cross- sectional 
nature, cause and effect of the observed associations cannot be defined. Second, 
urinary levels of either properdin and SC5b-9 might not accurately reflect what is 
really going on in the kidney since tubular binding may alter urinary excretion. 
In conclusion, we show that properdin is present in urine of proteinuric 
patients and that its presence is associated with worse renal function. The 
presence of urinary properdin excretion is associated with higher urinary 
levels of SC5b-9, the terminal product of complement activation, independent 
urinary properdin excretion is associated with intrarenal complement activation
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of the degree of proteinuria and renal function. We hypothesize that 
properdin promotes intratubular complement activation. Further research on 
the relation between urinary properdin excretion and complement activation 
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South Asians have a high prevalence of diabetes and cardiovascular 
complications. Since traditional risk factors only partially explain this excessive 
risk, the identification of non-traditional risk factors is warranted. Among 
these, central obesity might be an important determinant of cardiovascular 
disease in this specific group.
Methods 
We conducted a prospective observational study. A cohort consisting of 168 
type 2 diabetic South Asians was followed for a median duration of 7.66 (IQR 
7.48-8.1) years. The primary endpoint was the time to the first cardiovascular 
event, which was defined as the occurrence of either cardiovascular death, 
myocardial infarction, revascularization procedure, stroke, carotid artery 
desobstruction, peripheral artery revascularisation or amputation. To examine 
the effect of central obesity on cardiovascular events , Cox proportional hazards 
regression was performed.
Results
Out of 134 subjects for whom follow-up data were available, 30 subjects reached 
the primary endpoint. Waist-to-hip ratio was the principal predictor of 
cardiovascular events. Multivariate analysis for the occurrence of a 
cardiovascular event during follow-up revealed a hazard ratio of 3.77 (95% CI 
1.09-13.1), P = 0.037 ) for the highest versus the lowest tertile of waist-to-hip 
ratio.
Conclusion
Waist-to-hip ratio is a principal predictor of future cardiovascular events in 
type 2 diabetic South Asians. The underlying pathophysiologic mechanism 
probably involves adipogenic inflammation, dyslipidemia and adipokine 





South Asians have a high incidence of diabetes and subsequent vascular 
complications [1]. Traditional risk factors do not fully explain this higher 
incidence [2], so non-traditional risk factors must be involved. Among these, 
research has focused on central obesity, which is highly prevalent  in South 
Asians. At similar body mass index (BMI), South Asians have a higher percentage 
of body fat compared to Caucasian [3]. Moreover, fat distribution is different, 
with South Asians having a relatively high truncal fat mass [4]. Histomorphol-
ogy of adipocytes in South Asians also differs from that in Caucasians [5], with 
South Asians having larger adipocytes which are considered dysfunctional 
compared to normal sized adipocytes [6].
Cross-sectional studies in South Asians demonstrate that central obesity is 
associated with several cardiovascular risk markers, such as increased 
C-reactive protein [7], insulin resistance and dyslipidemia [1], and urinary 
albumin/creatinine ratio [8]. Although these latter factors have been shown to 
be predictive for future cardiovascular events, prospective data on the role of 
central obesity itself in predicting cardiovascular events in diabetic South 
Asians are lacking.
We performed a prospective study in a cohort of 168 diabetic South Asians to 
examine the effect of central obesity on cardiovascular events. 
Methods
Design of the follow-up study
We conducted a prospective follow-up study. All studied subjects were recruited 
from a previously published study [9]. The original study population comprised 
465 South Asians. At baseline, subjects that were not known with diabetes 
underwent a 75 g oral glucose tolerance test. Diabetes was diagnosed based on the 
ADA 2003 criteria. Out of 465 subjects, 168 subjects had type 2 diabetes at baseline 
(122 already known with diabetes, 46 newly diagnosed), and from these subjects 
follow-up data were collected. The study protocol was approved by the Institutional 
Medical Ethics Committee. All subjects provided informed consent.
Study-patients were followed up by letter and subsequently by phone. When 
subjects could not be traced by address or phone number in our database, 
general practitioners or participating family members were involved. 
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Follow-up data consisted of medical history with regard to cardiovascular 
events. Subjects were sent a questionnaire and were invited for a visit to our 
out-patient clinic. During this visit the questionnaire was reviewed by the 
main investigator (M.A.S.). Subjects not willing to visit the out-patient clinic 
were asked permission to collect medical data from their general practitioner. 
For subjects who had died during the follow-up period, cause of death and 
cardiovascular history was retrieved from the general practitioner. All (self-)
reported events were verified by contacting the hospital in which the event had 
occurred.
Measurements at baseline
Anthropometric measures at baseline included weight, height and waist- and 
hip circumference. Hip circumference was measured at the maximum hip 
circumference, waist circumference was measured at the point midway 
between the lower costal margin and the anterior superior iliac crest.
Laboratory measurements at baseline included lipids, creatinin, fasting 
glucose, fasting insulin, high-sensitivity C-reactive protein (hsCRP), adiponectin 
and serum complement factor 3 (C3) Lipids, creatinin, glucose an insulin were 
measured according to standard methods. High-sensitivity C-reactive protein 
was measured with a fully automated Cobas Integra 800, according to the 
manufacturers proceedings (Roche, Almere, the Netherlands). The variation 
coefficients (VC) were below 3 %. Adiponectin was measured with a radio-
immunoassay after dilution. The interassay VC’s ranged from 6.9 to 9.2 % at 
different levels (Millipore Corporation, Billerica, MA 01821, USA ). Serum C3 
concentration was quantified using radial immunodiffusion according to 
Mancini, using a polyclonal rabbit anti-human C3 anti-serum as described 
earlier [10]. Homeostatic model assessment for assessing insulin resistance 
(HOMA-IR) was performed as follows: [fasting insulin concentration (mU/L) x 
fasting glucose concentration (mmol/L)] / 22.5 [11].  
Definition of endpoint
Cardiovascular events were defined as the occurrence of either a myocardial 
infarction, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary 
Artery Bypass Grafting (CABG), stroke, Carotid Artery Desobstruction, 
peripheral vascular angioplasty, bypass or amputation, or sudden cardiac 
death. The latter was defined as a witnessed sudden circulatory arrest. The 




Normally distributed variables are expressed as mean ± 1 standard deviation 
and skewed distributed variables as median and interquartile range. Differences 
between two groups were assessed by Student’s t-test or Mann-Whitney-U test 
as appropriate. Differences between more than two groups were assessed by 
analysis of variance, adjusting for multiple comparisons according to 
Bonferroni. Correlations were assessed using Pearson’s correlation, skewed 
distributed variables being log-transformed. To identify predictors of 
cardiovascular events and to adjust for potential confounding factors, Cox 
proportional hazards regression was performed. Survival curves were compared 
using the Log-Rank test. All test were two-sided and the level of significance 
was set at 0.05. All analyses were performed using SPSS for windows, version 17.
Results
Out of 168 type 2 diabetic subjects at baseline, 21 could not be traced and 13 
subjects refused to participate. Eighty-six subjects visited the out-patient clinic, 
31 subjects did not visit the out-patient clinic but medical information was 
retrieved from the general practitioner, and 17 subjects had died (see below). 
The median duration of follow-up was 7.66 (IQR 7.48-8.10) years. Participants 
lost to follow-up did not differ in baseline characteristics from participants in 
whom follow-up data were available (table 1).
During follow-up, 39 cardiovascular events occurred in 30 subjects (16 men, 14 
women): 3 sudden cardiac deaths, 2 fatal and 5 non-fatal myocardial infarction, 
13 percutaneous coronary interventions, 8 coronary artery bypass graft 
procedures, 2 fatal and 5 non-fatal strokes, 1 lower extremity amputation. Eleven 
of these 30 subjects had already experienced a cardiovascular event at baseline. 
Ten subjects died due to non-cardiovascular causes. Two of these subjects reached 
the primary end-point before they died, the other 8 were censored.
The characteristics of the 134 subjects in whom follow-up data were available 
are shown in relation to waist-to-hip ratio (WHR) tertile in table 2. As expected, 
there were more women in the lowest WHR tertile and more men in the highest 
WHR tertile. Compared to subjects in the lowest WHR tertile, subjects in the 
highest WHR tertile had higher fasting triglycerides, lower HDL cholesterol 
levels, higher urinary albumin/creatinine ratio, and a higher prevalence of 
baseline cardiovascular events. Men and women differed only with respect to 
waist-to-hip ratio is a principal predictor of cardiovascular events
6
104
HDL cholesterol level (mean 1.11 ± 0.25 versus 1.32 ± 0.34 mmol/L in men and 
women, respectively,  P<0.001). All other parameters were not different between 
men and women (data not shown). 
Waist-to-hip ratio correlated weakly with adiponectin concentration (r = -0.213, 
P = 0.016), HDL cholesterol (r = -0.248, P = 0.004), HOMA-IR (r = 0.180, P = 0.040), 
fasting triglycerides (r = 0.211, P = 0.016) and urinary albumin/creatinine ratio 
(r = 0.180, P = 0.039) but not with hsCRP, C3, total cholesterol and BMI.
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Table 1    baseline characteristics of the study population
Follow-up 
(n=134)
Lost to follow-up 
(n=34)
P-value
Age (years) 50.7 ± 11.2 48.9 ± 11.2 0.392
% male sex 46 45 0.886
Diabetes duration (years) 7.0 (0-13) 5.0 (0-11) 0.519
HOMA-IR* 7.4 (4.8-12.3) 7.7 (5.3-12.1) 0.841
HbA1c (%) 7.7 ± 1.8 7.7 ± 2.0 0.976
Systolic blood pressure (mm Hg) 138 ± 24 140 ± 27 0.638
Diastolic blood pressure (mm Hg) 84 ± 11 84 ± 11 0.937
Urinary albumin/creatinine  ratio 
(mg/mmol)
1.0 (0.4-4.6) 1.0 (0.4-5.0) 0.991
High-sensitivity C-reactive protein 
(mg/L)
3.5 (1.8-8.0) 4.8 (1.7-8.4) 0.851
Cockroft-Gault creatinine clearance 
(ml/min)
86 ± 27 93 ± 20 0.205
Total cholesterol (mmol/L) 5.1 ± 1.0 5.0 ± 0.9 0.666
Fasting triglycerides (mmol/L) 1.59 (1.16-2.32) 1.46 (1.24-2.13) 0.869
HDL-cholesterol (mmol/L) 1.23 ± 0.3 1.28 ± 0.3 0.954
Ratio total cholesterol: HDL-
cholesterol
4.14 (3.45-5.05) 4.20 (3.10-5.0) 0.432
Body Mass Index 28.0 ± 4.7 28.4 ± 4.0 0.551
Waist-to-hip ratio 0.97 (0.93-1.03) 0.99 (0.95-1.04) 0.223
Adiponectin (mg/L) 7.6 (5.3-10.6) 6.8 (4.6-9.4) 0.124
Serum C3 (µg/ml) 871 ± 100 895 ± 78 0.226
% previous cardiovascular event 14 11 0.663
% current or previous smoker 45 39 0.528
*HOMA-IR = Homeostatic model assessment for assessing insulin resistance
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Cox proportional hazard regression
In univariate analysis an increased waist-to-hip ratio was a predictor of 
cardiovascular events (hazard ratio 6.4 (95% CI 1.9-21.9), P = 0.003 for the 
highest versus the lowest WHR tertile, see table 3). In figure 1, the event-free 
survival curves for the lowest and the highest WHR tertile are shown for 8 
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Table 2    baseline characteristics of 134 type 2 diabetic South Asians 
according to WHR tertile
WHR tertile 1 2 3
Age (years) 48.9 ± 12.2 50.8 ± 10.2 52.5 ± 11.0
% male sex 16 55* 64*
Diabetes duration (years) 6.0 (0.7-13.0) 4.0 (0.0-10.0) 10.5 (0.0-16.3)
HOMA-IR‡ 6.26 (4.38-9.93) 7.73 (4.33-10.46) 8.6 (6.0-11.8)
HbA1c (%) 7.3 ± 1.6 7.7 ± 2.2 8.0 ± 1.6
Systolic blood pressure (mm Hg) 138 ± 27 133 ± 16 145 ± 27
Diastolic blood pressure (mm Hg) 85 ± 10 81 ± 11 87 ± 13
Urinary albumin/creatinine ratio 
(mg/mmol)
0.80 (0.34-2.76) 0.73 (0.33-3.20) 2.74 (0.7-14.9)*†
High-sensitivity C-reactive protein 
(mg/L)
3.9 (2.2-9.3) 3.5 (1.7-9.4) 3.2 (1.3-5.9)
Cockroft-Gault creatinine  
clearance (ml/min)
92 ± 31 90 ± 27 94 ± 37
Total cholesterol (mmol/L) 5.22 ± 0.98 5.13 ± 1.02 5.10 ± 0.97
Fasting triglycerides (mmol/L) 1.28 (1.03-1.61) 1.70 (1.10-2.63) 1.79 (1.37-2.61)*
HDL-cholesterol (mmol/L) 1.36 ± 0.37 1.17 ± 0.25* 1.16 ± 0.29*
Ratio total cholesterol: HDL-
cholesterol
4.04 ± 1.24 4.57 ± 1.41 4.51 ± 0.92
Body Mass Index 28.3 ± 5.0 26.0 ± 3.6 28.6 ± 5.1
Adiponectin (mg/L) 8.8 (6.5-13.0) 7.0 (4.8-9.3)* 7.6 (5.7-11.7)
Serum C3 (µg/ml) 887 ± 83 869 ± 90 859 ± 124
% previous cardiovascular event 5 7 27*†
% current or previous smoker 39 48 52
Follow-up duration (years) 7.7 (7.5-8.1) 7.8 (7.5-8.1) 7.7 (7.3-8.2)
In the analysis of variance, skewed distributed variables were log-transformed.
*/† Significant difference ( P < 0.05) compared  to tertile 1 (*) or  tertile 2 (†)
‡HOMA-IR = Homeostatic model assessment for assessing insulin resistance
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Table 3    predictors of cardiovascular events




                       Lowest tertile 1.0 (reference) 1.0 (reference)
                      Middle tertile 2.46 (0.6-9.6) 2.3 (0.6-9.6)
                      Highest tertile 6.4 (1.9-21.9) 4.87 (1.25-18.93)
Age (years) 1.02 (0.99-1.06) 1.0 (0.95-1.05)
Male sex 1.51 (0.74-3.12) 0.88 (0.37-2.13)
Systolic blood pressure per 10 mm Hg 1.14 (0.98-1.32) 1.01 (0.98-1.03)
HbA1c (%) 1.22 (1.02-1.46) 1.17 (0.91-1.51)
Diabetes duration (years) 1.03 (0.995-1.07) 1.0 (0.94-1.06)
Total cholesterol (mmol/L) 1.20 (0.81-1.80) 1.33 (0.86-2.05)
Current or former smoker 1.27 (0.61-2.62) 1.08 (0.44-2.63)
Cardiovascular event at baseline 5.1 (2.3-11.1)
urinary albumin/creatinine ratio (mg/
mmol)#
1.97 (1.36-2.83)
plasma adiponectin concentration (mg/L)# 4.96 (0.73-33.72)
Body Mass Index 1.0 (0.91-1.08)
HOMA-IR†# 0.93 (0.26-3.27)
high-sensitivity C-reactive protein (mg/L)# 1.37 (0.60-3.13)
fasting triglycerides (mmol/L)# 1.84 (0.37-9.19)
HDL-cholesterol (mmol/L) 1.85 (0.57-6.03)
Ratio total cholesterol:HDL-cholesterol 0.93 (0.69-1.27)
Cockroft-Gault creatinine  clearance (ml/
min)
0.99 (0.98-1.01)
Serum C3 (µg/ml) 1.002 (0.997-1.006)
*  Included as covariates are waist-to-hip ratio, age, sex, systolic blood pressure, HbA1c, diabetes 
duration, total cholesterol, and smoking status.
# skewed distribuited variables were log-transformed
† HOMA-IR = Homeostatic model assessment for assessing insulin resistance
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years of follow-up. In addition to WHR, urinary albumin/creatinine ratio, a 
cardiovascular event at baseline and HbA1c  were associated with the occurrence 
of cardiovascular events. 
In multivariate analysis with age, sex, systolic blood pressure, HbA1c, diabetes 
duration, total cholesterol and smoking as covariates, only waist-to-hip ratio 
remained independently associated with the occurrence of cardiovascular 
events (multivariate HR 3.77(95% CI 1.09-13.1), P = 0.037 for the highest versus 
the lowest WHR tertile). The association remained after adjusting for a 
cardiovascular event at baseline (HR 4.84 (95%CI 1.36-17.2) for the highest 
versus the lowest WHR tertile). When only subjects without a prior 
cardiovascular event were analyzed, the association remained signifi cant 
(univariate HR 8.04, 95% CI 1.79-36.04. P = 0.006, multivariate HR 7.1, 95% CI 
1.24-40.9, P = 0.028). When men and women were analyzed separately, WHR 
above the median was associated with cardiovascular events (univariate HR 5.9 
(95%CI 1.32-26.7, P = 0.02) and 3.6 (95%CI 1.0-13.0, P = 0.05), in men and women 
respectively. Multivariate HR with age, HbA1c, diabetes duration, systolic blood 
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Figure 1    
Unadjusted Kaplan-Meier survival curves according to waist-to-hip-ratio tertile (solid line =  
fi rst / lowest WHR tertile, dashed line = third / highest WHR tertile). The highest WHR tertile 
has a worse event-free survival compared to the fi rst WHR tertile (Log rank test P = 0.016).
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pressure, smoking status and total cholesterol was not statistically significant 
(multivariate HR 4.56 (95%CI 0.89-23.3, P = 0.069) and 2.9 (95%CI 0.71-12.0, P = 
0.137), in men and women respectively.
To identify possible mediators by which central obesity might influence 
cardiovascular risk, we separately adjusted for adiponectin concentration, 
hsCRP, complement C3, HOMA-IR, fasting triglycerides, total cholesterol, and 
HDL-cholesterol. However, the association of WHR and cardiovascular events 
was not attenuated by any of these covariates (data not shown). 
Discussion
The current study demonstrates that waist-to-hip ratio, as a measure of central 
obesity, is a principal predictor of cardiovascular events in type 2 diabetic 
South Asians. Studies from different parts in the world report an increased 
prevalence of insulin resistance and diabetes in South Asians. South Asians 
develop diabetes 10 years earlier than Caucasians and therefore are exposed to 
a greater degree of cumulative glycemic damage to the vasculature [12]. Indeed, 
cardiovascular complications are more frequent in South Asians [13]. We 
previously studied South Asians living in the Netherlands, showing that central 
obesity is associated with albuminuria, even in the non-diabetic state [8]. These 
findings underscore the importance of developing effective preventive 
strategies for this specific population.
Instead of being an inert energy storage pool, visceral adipose tissue is an 
active regulator of metabolism [14]. Central obesity is associated with insulin 
resistance and dyslipidemia [15,16]. In addition, adipose tissue produces 
cytokines, complement factors and over 30 so-called adipokines [6]. Adipose 
tissue, as a source of pro-inflammatory cytokines, might drive chronic -vascular- 
inflammation (“adipogenic inflammation”) [17]. Several studies show increased 
CRP levels in South Asians compared to Caucasians [7,18,19], indicating that an 
increased pro-inflammatory state is present in this ethnic group. However, so 
far, data on the predictive role of hsCRP for cardiovascular events in this 
specific group were lacking. In our type 2 diabetic South Asians, hsCRP was not 
a predictor of cardiovascular events. 
Complement factor C3, which is also produced by adipose tissue [20], is the 
central molecule in the complement cascade. Compared to Caucasians, South 
Asians have increased levels of complement C3 [21,22]. As the complement 
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system is involved in atherogenesis [23], enhanced complement activation 
might contribute to increased atherogenicity in South Asians [21]. However, 
while in South Asians serum C3 is strongly associated with the metabolic 
syndrome [24], we did not find such a relationship with cardiovascular events 
in our study.
A previous cardiovascular event and a high urinary albumin/creatinine ratio 
were both associated with future cardiovascular events. In contrast to WHR, 
which likely has a pathophysiological link to cardiovascular events, this 
association likely reflects established end-organ damage. In addition, diabetes 
duration and HbA1c predicted cardiovascular events, pointing at the importance 
of cumulative glycemic damage to the vasculature. 
Adjustment for hsCRP, complement C3, adiponectin, HOMA-IR, and various 
lipid parameters did not attenuate the strong predictive value of WHR for 
cardiovascular events. This suggests that neither insulin resistance, 
dyslipidemia, increased inflammation, complement or adiponectin levels alone 
can explain the association between central obesity and cardiovascular events. 
These factors likely act in concert. 
A limitation of our study is the relatively small sample size which may limit 
the detection of predictors with smaller effects in this ethnic group.
In conclusion, we show that in patients with type 2 diabetes of  South Asians 
descent living in a western society, waist-to-hip ratio is a principal predictor of 
future cardiovascular events. This warrants interventions aimed at weight loss 
and reduction of central abdominal fat mass to determine whether this will 
lead to a decline in cardiovascular events. 
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South Asians have a high burden of cardiovascular disease. Connective Tissue 
Growth Factor (CTGF), a profibrotic cytokine, has evolved as a risk marker for 
cardiovascular disease. The current study explores the relation between CTGF 
and vascular damage in type 2 diabetic South Asians.
Research design and methods
We performed a cross-sectional study in 54 type 2 diabetic South Asians. 
Vascular function testing (measurement of aortic Pulse Wave velocity an 
carotid artery Intima Media Thickness) was performed and plasma CTGF level 
and  clinical parameters were assessed. The correlation between plasma CTGF 
level and measures of vascular damage was determined.
Results
Plasma CTGF correlated with pulse wave velocity (r = 0.424, P = 0.002),  carotid 
artery intima-media thickness (r = 0.324, P = 0.021) and urinary albumin-to- 
creatinin ratio (r = 0.376, P = 0.005).
Conclusion
Plasma CTGF level is associated with vascular and renal damage in type 2 




Subjects of South Asian descent have a high burden of type 2 diabetes and 
cardiovascular disease. Type 2 diabetes presents at a younger age and once 
present, the risk of diabetic nephropathy is increased compared to Caucasians [1]
Connective Tissue Growth Factor (CTGF) is a pro-fibrotic cytokine that is linked 
to development of vascular and renal disease [2,3].
Our aim was to determine the potential role of CTGF as a marker of vascular 
and renal dysfunction in subjects with type 2 diabetes of South Asian descent.
 
Methods and materials
Patient population and measurement of clinical parameters
All subjects belonged to a group of 465 South Asians that was previously studied 
[4] Patients with type 2 diabetes at baseline (n = 168) were contacted. Fifty-four 
patients agreed to participate in the current study. Data concerning medication, 
cardiovascular history and smoking habits were collected. Anthropometric 
measurements included weight, length, waist- and hip circumference. 
Laboratory parameters including lipids, creatinine, glucose, and urinary 
albumin/creatinine ratio (ACR) were measured according to standard methods. 
High sensitivity C-reactive protein (hsCRP) was measured with a fully automated 
Cobas Integra 800, according to the manufacturers protocol (Roche, Almere, 
the Netherlands). CTGF was measured in EDTA plasma drawn at study entry 
that had been stored at -80°C. CTGF was determined by a sandwich ELISA using 
monoclonal antibodies against two distinct epitopes on the N-terminal part of 
human CTGF (FibroGen, San Francisco, CA) detecting both full-length and 
N-terminal CTGF as described previously (2). 
The study was approved by the Institutional Medical Ethics Committee. All 
subjects provided informed consent.
 
Assessment of pulse wave velocity and intima-media thickness
Arterial stiffness was assessed noninvasively by determination of  the pulse 
wave velocity (PWV). Aortic PWV was calculated as the distance of the pulse 
wave traveling from the base of the neck to the right femoral artery per time 
frame (in m/s) as described previously [5]. For assessment of intima-media 
thickness (IMT) of the common carotid artery as a measure of atherosclerosis 
connective tissue growth factor is associated with vascular and renal damage
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the mean of eight ultrasound measurements (four measurements at different 
angles at each side of the neck) was taken as described previously [6]. All 
measurements were performed with subjects in the fasting state.
Statistical analysis
Normally distributed variables are expressed as mean ± 1 standard deviation 
and skewed distributed variables as median and interquartile range. 
Correlations were assessed using Pearson’s correlation, with skewed distributed 
variables being log-transformed. Partial correlation was used to adjust for 
covariates. All test were two-sided and the level of significance was 0.05. All 
analyses were performed using SPSS for windows, version 17.
Results
Fifty-four type 2 diabetic South Asians were studied. Baseline characteristics 
are shown in table 1. 
Median plasma CTGF level was 183 pmol/L (IQR 103-335). Plasma CTGF level 
positively correlated with PWV (r = 0.424, P = 0.002), carotid artery IMT (r = 0.324, 
P = 0.021), and log transformed urinary ACR (r = 0.376, P = 0.005). Plasma CTGF 
also positively correlated with age (r = 0.310, P = 0.023) but not with glycemic 
control (HbA1c r = 0.028, P = 0.841), systolic blood pressure (r = 0.259, P = 0.059), 
markers of inflammation (hsCRP r = 0.102, P = 0.461), or lipid parameters. 
Adjustment for age and sex did not affect the relation between plasma CTGF 
and PWV and urinary albumin/creatinine ratio (r = 0.376, P = 0.007 and r = 0.396, 
P = 0.004, respectively) but the relation between plasma CTGF and IMT was no 
longer statistically significant ( r = 0.260, P = 0.071). After addition of systolic 
blood pressure as a covariate to age and sex, only the relationship between 
CTGF and urinary albumin/creatinine ratio remained significant (r = 0.367, 
P = 0.009)
Pulse wave velocity additionally correlated with systolic blood pressure (r = 0.504, 
P < 0.001), BMI (r = 0.307, P = 0.027), waist circumference (r = 0.331, P = 0.017), 
hip circumference (r = 0.292, P = 0.036), HbA1c (r – 0.344, P = 0.013), Cockroft-Gault 
creatinin clearance (r = -0.282, P = 0.043), fasting triglycerides (r = 0.345, 
P = 0.013) and LDL-cholesterol (r = -0.354, P = 0.011), but not with age, sex, 
smoking status, urinary albumin/creatinine ratio, and high-sensitivity C-reactive 
protein. After adjustment for age, sex, systolic blood pressure, fasting 
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triglycerides, LDL cholesterol, HbA1c and Cockroft-Gault creatinin clearance, 
waist circumference remained independently associated with pulse wave 
velocity (r = 0.308, P = 0.045). 
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Table 1    Baseline characteristics of the study population
Age 56.8 ± 6.9
male sex (%) 48
Diabetes duration (yrs) 14 ± 6.3
HbA1c (%) 7.5 ± 1.4
Systolic bloodpressure (mm Hg) 147 ± 20
Diastolic bloodpressure (mm Hg) 88 ± 11
Body Mass Index 28.8 ± 4.4
Waist circumference (cm) 102 ± 12.8
Total cholesterol (mmol/L) 4.17 ± 0.88
LDL-cholesterol (mmol/L) 2.52 ± 0.82
HDL-cholesterol (mmol/L) 1.30 ± 0.35
Fasting triglycerides (mmol/L) 1.21 (0.98-1.80)
Previous cardiovascular event (%)$ 26
Retinopathy (%) 74
Current or former smoking (%) 44
Oral anti-hyperglycemic agents withour insulin (%) 52
Insulin (%) 11
Oral anti-hyperglycemic agents with insulin (%) 37
Urinary albumin/creatinine ratio (mg/mmol) 1.7 (0.7-5.3)
Cockroft clearance (ml/min) 101 ± 35
$  cardiovascular event is defined as a myocardial infarction, percutaneous transluminal coronary 
angioplasty, coronary artery bypass graft or stroke
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Discussion
The current study demonstrates that in patients with type 2 diabetes of South 
Asian descent, plasma level of CTGF correlates with vascular and renal damage. 
These data suggest that the profibrotic cytokine CTGF may play a role in diabetic 
vascular and renal disease.
CTGF is produced by several cell types (including endothelial cells, vascular 
smooth muscle cells, renal mesangial and tubular epithelial cells) and its 
biological functions include proliferation, angiogenesis, migration, adhesion, 
and extracellular matrix production [7]
An increasing body of evidence points to the importance of vascular fibrosis in the 
pathogenesis of cardiovascular complications [8]. Decreased vascular elasticity 
results in systolic hypertension leading to an increased cardiac workload. 
Our data indicate that CTGF, independent of age, may be a mediator of these 
changes given its profibrotic actions. Supporting this hypothesis, FG-3019, a 
CTGF inhibiting recombinant antibody, counteracted vascular fibrosis in 
diabetic rats [9].
Diabetic nephropathy occurs early in patients with type 2 diabetes of South 
Asian descent and blood pressure was shown to be a progression factor also in 
this subgroup [10]. Independent of blood pressure, plasma CTGF was strongly 
associated with urinary albumin/creatinin ratio as a measure of renal disease. 
Our data contribute to the observation that CTGF plays an important role in 
the pathophysiology of diabetic nephropathy [11]. A recent study showed 
reduction in albuminuria after administration of the CTGF-blocker FG-3019 to 
albuminuric patients with diabetes [12]. 
PWV was independently associated with waist circumference. The association 
between vascular stiffness and -mainly abdominal- obesity has been previously 
reported, and a beneficial effect of weight reduction on vascular stiffness has 
been shown [13]. Compared to Caucasians, South Asians have an increased 
prevalence of central obesity. We recently showed that in South Asians a high 
waist-to-hip ratio is a principal predictor of cardiovascular events [14].Vascular 
stiffness therefore might be an important link between central obesity and 
increased cardiovascular events in South Asians. 
In conclusion, plasma CTGF is associated with vascular stiffness, increased 
intima-media thickness and albuminuria in patients with type 2 diabetes of 
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Subjects of South Asian descent have an increased prevalence of type 2 diabetes 
[1,2].  Reduced insulin-sensitivity of glucose-utilizing tissues (insulin resistance) 
is central in the pathogenesis of  type 2 diabetes. Insulin resistance in its turn 
is strongly associated with - mainly visceral- obesity. South Asians have a 
preferential truncal (deep adipose tissue) fat distribution [3], and even at the 
same body mass index the amount of  -mainly visceral- fat is increased in South 
Asians [4]. Compared to the relatively inactive superficial subcutaneous adipose 
tissue (primary compartment), deep subcutaneous and visceral adipose tissue 
(secondary compartment, central obesity) is an active regulator of body 
metabolism [5]. Function and activity of the immune system is also influenced 
by the adipose tissue compartment [6-8]. Central adiposity is associated with 
chronic low-grade inflammation and activation of the immune system, 
apparently related to production of pro-inflammatory cytokines by infiltrating 
macrophages [9]. It is well-known that the inflammatory response is central in 
vascular diabetic complications, like atherosclerosis, ischemic heart disease, 
stroke, and nephropathy [10-14].  As a key player in the immune response, the 
involvement of the complement system is increasingly being recognized [15,16]. 
The complement system refers to a cascade of proteins which are involved in 
opsonisation of harmful particles such as bacteria and facilitate the 
inflammatory response by attraction of inflammatory cells and enhancing 
vascular permeability. This thesis explores the possible role of the complement 
system in diabetic vascular complications in type 2 diabetic subjects of South 
Asian descent.
Study population
The HINDINEF cohort offers an unique opportunity to study determinants of 
vascular complications in a population known for its high rate of renal and 
cardiovascular disease. At baseline the cohort was very well phenotyped, and 
both serum , plasma, urine and  DNA were available to perform additional 
studies. As expected, we observed a high rate of cardiovascular complications 
(39 events in 30 out of 134 subjects after 7.66 years of follow-up). 
Our study was performed in a selected population. Subjects had been selected 
based on either having a first-degree family member with end-stage diabetic 
renal disease (48 out of 168), or having a first-degree family member with type 
2 diabetes but without albuminuria (115 out of 168). A small number (5 out of 
168) was a second-degree relative of a subject with type 2 diabetes or had no 




study participants had a first-degree relative with type 2 diabetes. However, as 
the prevalence of type 2 diabetes in this specific population approaches 40% in 
those over the age of 60 [17], the chance of having a first-degree relative with 
type 2 diabetes is very high. Therefore, this selection-criterium is not a strong 
discriminator between our study population and type 2 diabetic subjects in 
the general South Asian population in The Hague. The other selection-criteri-
um (having a first-degree family member with end-stage diabetic nephropathy) 
is theoretically more discriminating, although a familial predisposition to 
diabetic nephropathy was not found previously [18]. Furthermore, the 168 
subjects described in this thesis originated from 89 different families. 
Therefore, taken together, we feel that our observations can be extrapolated at 
least to type 2 diabetic subjects in the general South Asian population in The 
Hague and surroundings. We lost 34 subjects to follow-up because they were 
unreachable. However, baseline clinical characteristics of subjects with and 
without available follow-up data were not different. Therefore, it is unlikely 
that an important selection bias was present in the recruitment of follow-up 
data. Of note, our population size was relatively small, which limits the 
detection of predictors of vascular complications with smaller effects.   
Functional meaning of increased C3 levels
In Chapter 2, we found increased levels of complement C3 -the central molecule 
in complement activation- in South Asians compared to a Caucasian control 
group. A key question is whether  increased C3 levels predispose to enhanced 
complement activation. Although we found increased levels of SC5b-9 - the 
effector molecule of complement activation – in South Asians compared to 
Caucasians, C3 levels were not correlated with SC5b-9 levels.  Thus C3 levels do 
not per se result in enhanced complement activation at the systemic level, 
although enhanced complement activation at tissue level cannot be ruled out. 
C3 levels were not associated with albuminuria, cardiovascular events or 
progressive renal failure and hence C3 in itself is not a useful cardiovascular 
risk marker in type 2 diabetic South Asians. Given the increased C3 level in the 
South Asian population, the inter-individual predictive value with respect to 
cardiovascular disease might be attenuated. This phenomenon has also been 
observed with other cardiovascular risk markers like adiponectin [19]
C3 levels were closely related to measures of adipose tissue mass (BMI, waist 
circumference, hip circumference). Indeed, C3 mRNA expression has been 
observed in –mainly omental- adipose tissue [20]. Adipocyte-derived C3 serves 
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as a precursor of C3adesarg , also called Acylation Stimulating Protein (ASP) 
[21]. C3adesarg is generated through interaction of C3 with complement factor 
B and the enzyme adipsin (also known as complement factor D). C3adesarg is 
inactive with respect to complement activation. Its main function is to increase 
triglyceride synthesis in fat-storing cells through stimulation of fatty acid 
incorporation. Increased C3 levels in South Asians thus might simply reflect 
increased central adipose tissue mass, although it is currently unknown to 
what extent adipocyte-derived C3 contributes to serum total C3 levels. 
Secondary mechanisms involving hepatic C3 production might also be 
involved.
Complement activation and nephropathy 
In the cross-sectional part of chapter 2, high plasma SC5b-9 levels were 
associated with albuminuria, and in the prospective part with progressive 
renal failure. This suggest that complement activation is linked to diabetic 
nephropathy, although the pathophysiologic mechanism remains to be 
clarified. We found no other data in the literature concerning plasma SC5b-9 
levels and renal disease. Plasma SC5b-9 not necessarily reflects intrarenal 
complement activation but rather might reflect complement activation due to 
general vascular inflammation and atherosclerosis, confounding the relation 
with nephropathy. 
Fibrosis is the ultimate final common pathway in the progression of chronic 
renal disease. Interestingly, both SC5b-9 and split products of C3 have been 
reported to induce renal fibrosis [22,53]. Histopathological studies show SC5b-9 
deposition in diabetic kidney biopsies, and  a correlation between C5b-9 
deposition and interstitial lesions has been reported [23].  Complement 
activation might thus be associated with renal fibrosis. SC5b-9 has also been 
detected in urine of subjects with macroproteinuric diabetic nephropathy [24], 
but its potential in predicting  progressive renal failure has not been 
determined.
 
Mannose-binding lectin (MBL): a two-edged sword
Mannose-binding lectin (MBL) is the primary recognition molecule of the lectin 
pathway of complement activation. MBL binds carbohydrate moieties on 
microorganisms, but endogenous MBL ligands, such as glycosylated immuno-
globulins or cells exposed to oxidative stress, have also been identified [25]. 




genotypes, commonly referred to as O-alleles) in the MBL gene (mbl2). Subjects 
with wild type MBL genotype (A/A) have the highest serum MBL levels, subjects 
with 1 variant allele (A/O) have intermediate levels and subjects with 2 variant 
alleles (O/O) have the lowest levels. In addition, polymorphisms in the promoter 
region influence the MBL level [26]. MBL has been introduced as a risk marker 
of cardiovascular complications in type 1 and type 2 diabetes [27,28]. However, 
the exact role of MBL, which previously  has been called  “the Dr. Jekyll and Mr. 
Hide of the innate immune system” [29] remains controversial.  On the one 
hand,  low MBL levels have been related to increased cardiovascular events 
[30,31], while on the other hand increased MBL levels were associated with 
diabetic nephropathy and enhanced ischemia/reperfusion injury [32,33]. In 
our study we found the same apparent paradox. In chapter 2, we found high 
MBL levels to be independently associated with progressive renal failure. 
Whether and how increased MBL levels result in increased renal damage 
remains to be clarified. In an experimental diabetic mouse model, MBL was 
associated with increased renal collagen expression [34], suggesting that high 
MBL levels might be related to renal fibrogenesis. However, the exact pathophys-
iological pathway is currently unresolved, although in vitro studies suggest 
that oxidative stress, which indeed is enhanced in the diabetic state,  might be 
an important trigger for MBL mediated complement activation [35]. 
In chapter 3 however, we found that the O/O MBL genotype, which results in 
low MBL levels, are associated with increased cardiovascular events, as was 
previously found by others [30,31]. A possible explanation for this observation 
might be a defective MBL mediated clearance of atherogenic particles [36]. MBL 
binds  N-acetylglucosamine moieties, which are expressed on several 
lipoproteins and oxidized LDL [37], and this may facilitate their phagocytic 
clearance. Additionally, MBL deficiency might influence the susceptibility and 
course of  infection with Chlamydia pneumoniae, which is associated with 
coronary artery disease [38]. Therefore, the role of MBL in micro- and 
macrovascular disease might involve different mechanisms: in the former, 
direct complement-mediated injury might be involved, whereas in the latter 
enhanced atherogenesis caused by diminished anti-atherogenic or anti-infec-
tious activity seems to be responsible. As genotype distribution was not 
different between South Asians and Caucasians, genetically determined 
differences in MBL levels are unlikely to explain the increased rate of vascular 
complications in South Asians.    
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Complement and progressive renal failure
Proteinuria is a prognostic marker in renal disease. Besides being a marker of 
renal damage, non-selective proteinuria is thought to be toxic to the tubuloint-
erstitium [39-42]. Activation of filtered or locally produced complement 
components is likely involved in tubulotoxicity of proteinuria [43,44]. 
Complement activation products are indeed detectable in urine of patients 
with different proteinuric renal disease [45-47]. Experimental studies in 
various proteinuric models show complement activation on tubular cell brush 
border [48-52]. Inhibition of complement, either by administration of a 
complement inhibitor or by knock-out of complement components, results in 
attenuation of tubulointerstitial damage [48,51,52]. Complement activation 
also has been linked to the induction of renal fibrosis [22,53]. Although the 
capacity of cultured tubular cells to activate the alternative complement 
pathway has long been known, the mechanism had not been determined. 
Properdin acts as a positive regulator of the alternative pathway of complement 
activation by stabilizing the alternative pathway C3-convertase, but more 
recent data suggest that properdin also acts as a recognition molecule of the 
alternative pathway [54-57]. In chapter 4, we demonstrate that properdin acts 
as a focal point for alternative pathway complement activation on cultured 
proximal tubular epithelial cells.  In chapter 5, we demonstrate that properdin 
is excreted in proteinuric renal disease and that “properdinuria” is associated 
with urinary SC5b-9 level and renal dysfunction. These results suggest that 
properdin promotes intrarenal complement activation and might contribute 
to proteinuria mediated renal damage.   
Central obesity as a risk factor for cardiovascular disease 
South Asians have an increased prevalence of central obesity. Cross-sectional 
studies in South Asians demonstrate that central obesity is associated with 
several cardiovascular risk markers, such as increased C-reactive protein level 
[58], insulin resistance and dyslipidemia [59], and urinary albumin/creatinine 
ratio [60], but the predictive value for cardiovascular events of central obesity 
itself had never been assessed. In chapter 6, we show that a high waist-to-hip 
ratio, as a measure of central obesity, is a principal predictor of cardiovascular 
events in type 2 diabetic South Asians. Instead of being an inert energy storage 
pool, visceral adipose tissue is an active regulator of metabolism [5] that 
produces cytokines, complement factors and over 30 so-called adipokines [61]. 




-vascular- inflammation (“adipogenic inflammation”) [9,62]. However, we could 
not find a single mediator (insulin resistance, inflammation, adiponectin, 
dyslipidemia, complement levels) that explained the effect of central obesity 
on cardiovascular events. All these factors likely act in concert. 
In addition,  central obesity was independently associated with arterial stiffness 
(see chapter 7 below) . Arterial stiffness leads to an increased cardiac workload 
resulting in left ventricular hypertrophy. Therefore, increased arterial stiffness 
might be an important link between central obesity and cardiovascular 
complications in type 2 diabetic South Asians.
Connective Tissue Growth Factor and vascular and renal damage 
In chapter 7 we studied the association of Connective Tissue Growth Factor 
(CTGF, a pro-fibrotic cytokine) with vascular and renal damage in 54 type 2 
diabetic South Asians. We found that plasma CTGF level is associated with 
pulse wave velocity (PWV, a measure of arterial stiffness), carotid artery 
Intima-Media Thickness (IMT, a measure of atherosclerosis) and urinary 
albumin/creatinine ratio (a measure of renal damage). CTGF level also predicts 
progressive renal failure in South Asian with type 2 diabetes (own observations, 
unpublished). Given its pro-fibrotic actions, CTGF might be an important 
mediator in vascular and renal fibrosis. 
Concluding remarks and future perspectives
In this thesis we studied several non-traditional risk factors for the progression 
of renal and cardiovascular disease in subjects with type 2 diabetes of South 
Asians descent. In the epidemiological studies incorporated in this thesis we 
focused on the role of adipose tissue and complement as mediators of damage. 
Additionally, we specifically studied the role of complement in the progression 
of proteinuric renal disease.
Our studies raise several clinical perspectives. First, as central obesity is the 
principal predictor of cardiovascular events in this specific population, weight 
reduction should be of primary importance in the reduction of cardiovascular 
risk. Although it has to be tested in an prospective intervention study, weight 
reduction might prove to be more effective than pharmacological interventions. 
One intriguing point to be addressed is the apparent overlap between the 
complement system and adipose tissue biology. Currently, no data exist 
regarding the Acylation-Stimulating Protein (ASP) pathway (see above) in South 
Asians.  As ASP deficiency is associated with reduced fat mass and increased 
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energy expenditure [63], the ASP pathway might be an interesting target in 
preventing the deleterious effects of central adiposity.
Second, as CTGF might be an important mediator of renal and vascular fibrosis, 
blocking its actions might open a new therapeutic avenue with respect to 
prevention of cardiovascular disease, as preliminary data suggest [64,65] Third, 
as complement activation is involved in the progression of proteinuric renal 
disease and properdin acts as a focal point, specifically blocking the interaction 
between properdin and the tubular brush border – without blocking the entire 
complement cascade-  might retard progression of renal damage. 
Of course, our studies raise new questions. The contribution of MBL to 
cardiovascular and renal damage should be further clarified. Is MBL an 
innocent bystander or a real mediator of progressive renal damage and if so, 
what is the pathophysiologic pathway involved? What is the relative contribution 
of low MBL levels to the process of atherosclerosis? It has been shown that high 
MBL levels after myocardial infarction are associated with an increased rate of 
re-infarction [66], suggesting that high MBL levels might prevent cardiovascular 
events, but are deleterious once an event occurs.
Proteinuria is an important predictor of progression of renal disease, and in 
our study urinary albumin/creatinine ratio was indeed associated with 
progressive renal failure. However, we were surprised that subjects with 
progressive renal disease had varying though overall mild degrees of baseline 
proteinuria (urinary albumin/ creatinine  ratio ranging from 2.56 to 662 mg/
mmol). Even in daily clinical practice, many subjects with chronic renal failure 
(including many diabetic subjects!) are seen with relatively little proteinuria. 
Although many studies address  the role of complement-induced renal damage 
in proteinuric renal disease (see above), the role of complement in the 
progression of non-proteinuric renal disease is largely an undeveloped area. 
South Asians have a 40-fold increased risk of reaching end-stage diabetic renal 
disease [67]. However, once on dialysis, they show an increased survival 
compared to Caucasians [68-70], while central obesity continues to be associated 
with decreased survival, even on dialysis [71]. Apparently yet undefined, 
initially harmful factors might lose their harmful potential or rather become 
protective in a dialysis setting. Interestingly, whereas high MBL levels are 
associated with progressive renal failure, in hemodialysis patients high MBL 
levels were shown to be associated with improved rather than worse survival 
[72]. As alternative pathway complement activation on the membrane of the 




influence morbidity and mortality on dialysis [73]. Therefore,  the role of 
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Hindoestanen (Engels: South Asians) zijn oorspronkelijk afkomstig van het 
Indiase subcontinent. In de 19e eeuw zijn velen van daaruit naar Suriname 
verscheept om te werken op de plantages. Na de onafhankelijkheid van Suriname 
in 1975 en tijdens de politiek instabiele periode daarna zijn veel Hindoestaanse 
Surinamers naar Nederland geëmigreerd, waar zij zich vestigden in en rond de 
grote steden. In Den Haag en omgeving telt de  Surinaams-Hindoestaanse 
gemeenschap rond 50.000 personen. 
Personen van Hindoestaanse komaf hebben een verhoogd vóórkomen van type 
2 diabetes mellitus (suikerziekte). Type 2 diabetes mellitus is geassocieerd met 
centrale adipositas (teveel buikvet), en ook dit komt bij personen van 
Hindoestaanse komaf vaak voor. Diabetes mellitus is geassocieerd met schade 
aan hart, bloedvaten en nieren leidend tot hartinfarct, beroerte en nierinsuf-
ficientie (onvoldoende nierfunctie), zelfs tot aan dialyse-noodzaak toe. Ook 
deze complicaties komen bij Hindoestanen vaker voor dan men zou verwachten. 
De precieze oorzaak hiervan is niet bekend.
Bij de ontstaanswijze van complicaties aan hart, bloedvaten en nieren staat een 
ontstekingsproces in bloedvaten en/of nieren centraal. Een teveel aan buikvet 
is geassocieerd met toegenomen  ontstekingsactiviteit.  Bij een ontstekingspro-
ces zijn allerlei afweercellen en eiwitsystemen betrokken. Een van die 
eiwitsystemen is het complementsysteem. Dit systeem bestaat uit ongeveer 30 
verschillende eiwitten die elkaar trapsgewijs activeren. De eiwitten van het 
complementsysteem brengen schade toe aan bacteriën, zorgen dat deze 
gemakkelijker door afweercellen opgeruimd kunnen worden, en bevorderen 
tevens de ontstekingsreactie. Het complementsysteem kan via 3 routes worden 
geactiveerd, en elke route heeft zijn eigen “gangmaker”-eiwit. Bij de lectine-route 
is dat Mannose-bindend lectine (MBL), dat onder andere suikerstructuren op 
bacteriën herkent. De hoogte van de MBL waarde in het bloed wordt voornamelijk 
genetisch bepaald. De twee andere routes worden op gang gebracht door im-
muuncomplexen (de klassieke route) of doordat spontaan optredende comple-
ment-activatie wordt gestimuleerd (alternatieve route). Dit proefschrift 
onderzoekt de mogelijke rol van het complementsysteem bij hart-, vaat- en nier-
complicaties in Surinaams Hindoestaanse type 2 diabeten.
De personen die aan dit onderzoek hebben meegewerkt zijn afkomstig uit een 
eerder uitgevoerde studie, de zogenaamde HINDINEF studie, die in de jaren 
1998-2000 465 Surinaamse Hindoestanen “in kaart heeft gebracht”. Het huidige 
nederlandse samenvatting
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onderzoek betreft een vervolgonderzoek onder alle Surinaamse Hindoestanen 
die destijds diabetes mellitus hadden (168 personen). Na een gemiddelde 
periode van 7,66 jaar werd nagegaan in hoeverre zij complicaties hebben 
ontwikkeld aan hart, bloedvaten en nieren. Met de gegevens die uit het eerdere 
HINDINEF onderzoek waren verkregen is vervolgens gezocht naar factoren (en 
dan met name eiwitten van het complementsysteem) die geassocieerd zijn met 
het optreden van deze complicaties.  
In hoofdstuk 2 vinden we dat Surinaamse Hindoestanen hogere bloedwaarden 
hebben van complementeiwit C3, het centrale eiwit in het complementsysteem, 
vergeleken met blanke Caucasiers. Daarnaast hebben Surinaamse Hindoestanen 
ook hogere bloedwaarden van complementeiwit SC5b-9, het eindproduct van 
het complementsysteem. Dit zou erop kunnen wijzen dat het complement-
systeem bij Surinaamse Hindoestanen actiever is dan bij Caucasiers. Echter, de 
hoogte van zowel C3 als SC5b-9 waren niet voorspellend voor het optreden van 
hart-en vaatcomplicaties. Bovendien waren C3 en SC5b-9 waarden niet aan 
elkaar gecorreleerd. Een hoger C3 lijkt dan ook niet noodzakelijkerwijs te 
leiden tot toegenomen complementactivatie.  C3 waarden zijn wel gecorreleerd 
met maten voor de vetmassa (tailleomtrek, heupomtrek, overgewicht). 
Inderdaad is aangetoond dat vetcellen C3 kunnen produceren.  Dit C3 dient als 
voorloper voor Acylatie Stimulerend Proteine (ASP). ASP heeft als functie om 
vetzuren – die na de maaltijd in het bloed komen – op te nemen in vetcellen. 
Verhoogde C3 waarden bij Surinaamse Hindoestanen zijn dus wellicht een 
uiting van toegenomen vetmassa.
In hoofdstuk 3 vinden we dat het genotype (erfelijk materiaal)  dat zorgt voor 
lage MBL waarden in het bloed wél geassocieerd is  met het optreden van hart- 
en vaat complicaties. Behalve bij het bestrijden van bacteriën is MBL ook 
betrokken bij het opruimen van vetdeeltjes die schadelijk zijn voor bloedvaten 
en tot atherosclerose (in de volksmond “aderverkalking” genoemd) leiden. Bij 
lage MBL waarden verloopt deze opruimreacties onvoldoende, en dit zou 
mogelijk de verklaring kunnen zijn waarom een laag MBL-genotype geassocieerd 
is met hart-en vaatziekten. Ook zou een laag MBL gehalte een verhoogde 
vatbaarheid kunnen betekenen voor infecties met Chlamydia die in verband zijn 
gebracht met het optreden van atherosclerose. Opvallend genoeg zijn MBL 
waarden zelf niet voorspellend voor hart-en vaatziekten. Een eenmalige meting 
van MBL (zoals in onze studie) is wellicht onvoldoende nauwkeurig om de totale 




In tegenstelling tot hart-en vaatziekten was complementeiwit SC5b-9 wél 
geassocieerd met het optreden van nierfunctie verslechtering. Ook hoge MBL 
waarden waren geassocieerd met nierfunctieverslechtering. Dit zou kunnen 
duiden op betrokkenheid van het complementsysteem bij nierfunctie 
verslechtering, hoewel het exacte mechanisme niet is opgehelderd. Wellicht 
speelt toegenomen bindweefselvorming (fibrose) in de nier een rol. Er is wat 
MBL betreft dus een paradoxale situatie: een erfelijke aanleg voor lage MBL 
waarden is geassocieerd met hart-en vaartziekten, terwijl hoge waarden 
geassocieerd zijn met progressieve nierschade.
Hoofdstuk 4 en 5 gaan verder in op de rol van het complementsysteem bij 
progressieve nierschade.  Wanneer nieren beschadigd raken lekt er dikwijls 
eiwit in de urine (proteïnurie). Onder deze eiwitten bevinden zich ook comple-
menteiwitten, en die kunnen van binnen uit de nier verder beschadigen. Proef-
dierstudies laten zien dat wanneer het complementsysteem geremd wordt er 
minder nierschade optreedt. Het was al langer bekend dat met name de 
alternatieve route van complement activatie (zie boven) hierbij betrokken is, en 
dat complementeiwit C3 kan binden aan niercellen. Hoe deze binding tot stand 
komt was echter niet bekend. In hoofdstuk 4 laten wij zien dat een ander 
 complementeiwit, properdine genaamd, specifiek bindt aan niercellen. Deze 
binding van properdine, wat hier dus de functie van “gangmaker-eiwit” vervult, 
is essentieel voor het optreden van complement activatie. In hoofdstuk 5 tonen 
wij aan dat properdine inderdaad in de urine gevonden kan worden van patiënten 
(in dit geval geen Hindoestanen maar 70 willekeurige patiënten van de polikliniek 
nierziekten in het LUMC) die een duidelijk eiwitlek hebben. Properdine in de 
urine is vervolgens weer geassocieerd met SC5b-9 in de urine. Dit duidt erop dat 
properdine een belangrijke bijdrage levert bij de door het complement systeem 
toegebrachte nierschade. Wanneer het molecuul  geïdentificeerd kan worden 
waaraan properdine bindt is het in de toekomst wellicht mogelijk om proteïnurie-
 gemedieerde nierschade (deels) te voorkomen.
Zoals boven reeds vermeld hebben Hindoestanen een aanleg voor het 
ontwikkelen van teveel buikvet (centrale adipositas). De verhouding tussen 
buikomtrek en taille-omtrek (Engels: waist-to-hip ratio (WHR)) is een maat voor 
centrale adipositas. In hoofdstuk 6 beschrijven wij dat de WHR bij Surinaams-
Hindoestaanse type 2 diabeten de belangrijkste voorspeller is van hart-en 
vaatziekten. Personen met de hoogste WHR hadden een 5 x zo hoge kans op 
hart-en vaatziekten dan personen met de laagste WHR. Hoewel deze bevinding 
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nog niet bewijst dat vermindering van buikvet automatisch zal leiden tot 
minder hart- en vaatziekten, is het wel aannemelijk dat, specifiek in deze 
 bevolkingsgroep, een gezondere leefstijl beschermend werkt voor hart- en 
vaatziekten.
In hoofdstuk 7 beschrijven wij de resultaten van vaatfunctieonderzoek (IMT 
en PWV, zie verder) bij 54 Surinaams-Hindoestaanse type 2 diabeten. Tevens 
werden bloedwaarden gemeten van Connective Tissue Growth Factor (CTGF). 
Dit is een eiwit dat betrokken is bij bindweefselvorming (fibrose). Bij IMT 
meting (Intima-Media dikte) wordt met behulp van een echo-apparaat de 
 binnenbekleding van de halsslagader gemeten, en de dikte hiervan is een maat 
voor atherosclerose (“vaatverkalking”). Bij een PWV meting (Pulse Wave 
Velocity) wordt de snelheid gemeten waarmee een drukgolf zich via de 
bloedvaten voortplant. Hoe stijver het bloedvat, hoe sneller de drukgolf zich 
voortplant (hoge PWV). Stijve bloedvaten leiden tot een grotere belasting voor 
het hart, en er komen steeds meer aanwijzingen dat stijve bloedvaten het risico 
op hart-en vaatziekten voorspellen. Wij vonden dat CTGF waarden gecorreleerd 
zijn aan zowel IMT (maat voor vaatverkalking), PWV (maat voor vaatstijfheid) 
als  de mate van eiwit-lek in de urine (maat voor nierschade). Ook de tailleomtrek 
(als maat voor hoeveelheid buikvet) was geassocieerd met vaatstijfheid.  
Hoewel de vraag of en op welke manier CTGF bijdraagt aan vaat- en nierschade 
nog niet is opgehelderd, lijkt CTGF een veelbelovend aangrijpingspunt om  vaat- 
en niercomplicaties bij diabetes tegen te gaan. 
Vanuit dit proefschrift kunnen enkele verbanden worden gelegd naar de 
medische praktijk.  Aangezien centrale obesitas een belangrijke voorspeller is 
voor hart-en vaatziekten in Surinaams-Hindoestaanse type 2 diabeten, lijkt ge-
wichtsreductie een primair aangrijpingspunt bij het voorkómen van hart-en 
vaatziekte, hoewel de effectiviteit ervan natuurlijk nog moet worden bewezen. 
Fascinerend is de kennelijke overlap tussen het complementsysteem en de 
vetweefsel stofwisseling. Er zijn geen gegevens met betrekking tot ASP in 
Surinaamse Hindoestanen. Proefdierstudies tonen aan dat een tekort aan ASP 
leidt tot gewichtsreductie en toegenomen energieverbruik. ASP zou daarom 
een interessant aangrijpingspunt kunnen zijn in het voorkómen van de 
schadelijke effecten van centrale adipositas. 
De studies uit dit proefschrift roepen natuurlijk ook  nieuwe vragen op. De 
bijdrage van MBL aan hart-en vaatziekte en nierschade dient verder opgehelderd 
te worden. Met name is nog onduidelijk of MBL zelf echt schadelijk is of slechts een 
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epifenomeen (dwz een andere –onbekende- factor leidt zowel tot toegenomen 
nierschade als toegenomen MBL waarden)
Eiwitlekkage in de urine is een belangrijke voorspeller voor progressieve nier-
functieverslechtering. Het verbaasde ons echter dat de personen die een 
verslechtering van nierfunctie hadden helemaal niet zoveel eiwit in de urine 
lekten. Ook in de dagelijkse praktijk worden veel patiënten gezien met 
progressieve nierfunctieverslechtering maar slechts een gering eiwitlek. 
Hoewel de rol van het complementsysteem bij eiwitlekkage steeds duidelijker 
wordt is er hoegenaamd niets bekend over de rol van het complementsysteem 
wanneer er nauwelijks eiwitlek is.
Surinaamse Hindoestanen met type 2 diabetes hebben een bijna 40 keer zo 
hoge kans om door diabetes aan de dialyse te geraken. Echter, eenmaal aan de 
dialyse hebben zij een betere overleving dan Caucasische lotgenoten. De 
oorzaak hiervan is niet duidelijk. Er zijn blijkbaar - tot op heden onbekende- 
factoren die hun schadelijkheid verliezen of juist beschermend werken in dia-
lysepatiënten. Opmerkelijk genoeg heeft ook MBL zo’n “dubbel gezicht”: hoge 
MBL waarden zijn geassocieerd met achteruitgang van nierfunctie, maar bij di-
alysepatiënten zijn lage MBL waarden juist gekoppeld aan slechtere overleving. 
Complement activatie op het oppervlak van de kunstnier is een welbekend 
fenomeen, en het complementsysteem zou de overleving aan de dialyse kunnen 
beïnvloeden. Het zou daarom interessant zijn om de rol van het complement-
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In den beginne hield ik mijzelf voor geen promotietraject te ondernemen, 
aangezien ik mezelf primair als clinicus en niet als wetenschapper beschouw. 
Gelukkig kwam ik er op tijd achter dat het één het andere niet hoeft uit te 
sluiten en kan ik terugkijkend zeggen dat het goed was. 
Het moest gaan over de relatie tussen het complement-systeem en diabetes- 
gerelateerde complicaties. Het HINDINEF-cohort leek hiervoor bij uitstek 
geschikt en interessant: dat waren type 2 diabeten met een hoog  cardiovasculair 
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er al snel achter dat labwerk zich moeilijk met klinische taken laat combineren. 
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aan Tri Nguyen, Amelie Dendooven en Roel Goldschmeding voor de prettige 
samenwerking op het CTGF-artikel. En uiteraard Marko Mallat, die altijd bereid 
was om statistisch significante hulp te verlenen.
Uiteraard ben ik veel dank verschuldigd aan alle Surinaamse Hindoestanen die 
belangeloos aan het onderzoek hebben meegewerkt. Zonder hen zou dit 
proefschrift überhaupt niet bestaan En natuurlijk dank ik Prataap Chandie 
Shaw voor zijn noeste arbeid aan het HINDINEF cohort. Ik hoop dat ik met dit 
promotieonderzoek een steentje heb kunnen bijdragen aan de bestudering van 
een – zeker vanuit Surinaams Hindoestaans oogpunt – belangrijk probleem.
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